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 CHAPTER I 
 
INTRODUCTION 
 
PROSTATE CANCER 
Epidemiology: 
            Prostate cancer (PCa) is the most common cancer next to skin cancer, in 
American men. The American Cancer Society (ACS) estimates that during 2007 
about 218,890 new cases of prostate cancer will be diagnosed in the United States. 
Approximately, about 1 man in 6 will be diagnosed with prostate cancer during his 
lifetime. Prostate cancer is the second leading cause of cancer deaths next to lung 
cancer in American men. ACS estimates that 27,050 men in the United States will die 
of prostate cancer in 2007 comprising about 10% of cancer-related deaths in men.  
            Multiple risk factors (Figure 1) have been proposed to play role in the 
development of prostate cancer which include aging, environmental factors, familial 
inheritance and level of steroid hormones (Abate-Shen and Shen, 2000). Aging is the 
most significant risk factor for the development of prostate cancer. The chance of 
having prostate cancer rises rapidly after age 50 and about two thirds (2/3) of all 
prostate cancers are found in men over the age of 65. The incidence of prostate cancer 
in the United States is significantly higher than in Asian and African countries. 
Furthermore in the United States, African-American men are more likely to suffer 
from prostate cancer than white American men. African-American men present with 
advanced stage prostate cancer lesions predisposing them to higher death rates. 
 1
 Dietary and environmental factors play pivotal role in prostate carcinogenesis (Carter 
and Coffey, 1990). 
 
Age
Race Family history 
 
                         
Figure 1. Schematic of prostate cancer risk factors: Age, family history, 
race, environmental factors including diet and levels of androgens are some of 
the suggested risk factors for prostate cancer. 
         
 
              
            Prostate cancer runs in families and hereditary factors account for ~10% of 
prostate cancers and are often associated with early onset of disease (Carter et al., 
1992). Several studies have suggested an association between breast and prostate 
cancer (Anderson and Badzioch, 1993; Tulinius et al., 1992), but the molecular 
mechanisms are still unknown. Additionally, age-related decrease in the ratio of 
androgen to estrogen might provide a risk factor for the initiation of prostate cancer 
(Prehn, 1999). 
 
 
Diet 
Prostate cancer 
Environment 
Hormones
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 Prostate anatomy and development: 
            The prostate gland surrounds the urethra and is located posterior to the 
bladder. Although, the prostate gland produces important secretary proteins in the 
seminal fluid, it is not absolute for fertility. Adult human prostate is a small acorn 
shaped tissue with ductal-acinar histology. Morphologically, human prostate can be 
divided into three different zones (Figure 2): the peripheral zone, the transitional 
zone, and the central zone (McNeal, 1988). Benign prostatic hyperplasia (BPH), a 
non-malignant growth of prostate occurs mainly in the transitional zone while 
prostate carcinoma arises primarily in the peripheral zone.      
            During embryogenesis, prostate develops from urogenital sinus which is a 
derivative of hindgut. During gestation, primitive urogenital sinus is first separated 
from terminal hindgut through division of the cloaca by urorectal septum. The rostral, 
caudal and intermediate parts of the primitive urogenital sinus subsequently form 
urinary bladder, penile urethra and prostate respectively. The overall process of 
prostate development remains similar in both humans and mice but the maturation 
stage differs as the ductal morphogenesis occurs at puberty under the action of 
androgens in humans.  
            In mice, Nkx3.1 a homeobox gene is expressed in urogenital sinus epithelium 
prior to prostate development and is subsequently expressed in all stages of prostate 
development. Cunha, Hayward and colleagues have provided evidence that 
interactions between the epithelial and stromal components are essential for prostate 
development and differentiation utilizing tissue recombination technique (Cunha, 
1972a; Cunha, 1972b; Cunha et al., 1996; Hayward et al., 1997). In the fetus, 
 3
 testosterone stimulates budding of the prostate epithelium from urogenital sinus 
which produces growth factors like sonic hedgehog to activate underlying 
mesenchyme (Podlasek et al., 1999). On the other hand, paracrine signals of growth 
factors from mesenchyme are responsible for glandular morphogenesis and epithelial 
growth.  
 
 
 BPH 
Prostate 
Cancer 
Figure 2. Morphological zones of prostate gland: Human prostate gland is 
subdivided into three morphological zones namely, central zone, transitional zone 
(BPH prone zone) and peripheral zone (cancer prone zone) [adapted from 
McNeal 1969] 
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            The prostate consists of a fibromuscular stromal and a glandular epithelial 
compartment. Smooth muscle cells, fibroblasts and endothelial cells are the stromal 
components while the secretory luminal cells, basal cells and neuroendocrine cells are 
the epithelial components (Figure 3). Luminal epithelial cells produce prostatic 
secretory proteins. Prostate stem cells are suggested to be subpopulation of androgen 
independent basal cells.      
 
 
 
 
 
 
 
 
        
Figure 3. Schematic of cell types in prostate gland: Human prostatic duct 
epithelial compartment contains three different types of epithelial cells 
luminal (secretory) epithelium, basal epithelium and neuroendocrine cells. 
(Adapted from Abate and Shen 2000) 
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           A number of regulatory genes play significant role in the normal development 
of prostate summarized in (Table 1). 
                     
                   
                 Table 1. Candidate genes involved in prostate development 
 
Classification Genes 
Nuclear hormone receptor Androgen receptor (AR) 
Homeodomain transcription 
factor 
Nkx3.1 
HoxD13 
Forkhead box transcription 
Factor 
FoxA1 
FoxA2 
Secreted signaling factors Sonic hedgehog (Shh) 
BMP-4 
Growth factors 
 
 
FGF7 
FGF10 
TGFß1 
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 Molecular genetics of prostate cancer: 
           The development and progression of prostate cancer is complex and believed 
to involve sequential accumulation of multiple genetic changes. Although ~ 10% 
tumors can have inherited genetic mutations (Table 2), essentially all the tumors 
acquire genetic alterations during the course of tumorigenesis. The multistep model 
for prostate tumor progression is depicted in (Figure 4). Several oncogenes are 
activated in the process of carcinogenesis by different mechanisms such as gene 
amplification, translocations, or point mutations. Many tumor suppressor genes are 
also inactivated by the loss of heterozygosity (LOH) or inactivation of the other allele 
by a mutation (Dong, 2006). Recently, haploinsufficiency at tumor suppressor loci 
and epigenetic changes including DNA hypermethylation or histone modifications 
have also been proposed as mechanisms in the progression of prostate cancer. Some 
of the multiple genes involved in the initiation / progression of prostate cancer are 
summarized in (Table 3). 
                Table 2. Genes implicated in familial prostate cancer 
Gene or locus Chromosomal 
locus 
 
Mode of 
inheritance 
 
 
HPC1 
PCAP 
CAPB 
HPCX 
HPC20 
ELAC2/HPC2 
 
1q24-25 
1q42.2-43 
1p36 
Xq27-28 
20q13 
17p11 
 
 
AD 
AD 
AD 
X-linked/AR 
AD 
AD 
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 Prostate Cancer- Multi step model
Benign
PIN Carcinoma
Metastases
Nkx3.1 PTEN       p53MYC
Egr1
Pim-1
p27
Androgen Receptor Signaling
 
 
Figure 4. Multi-step model for prostate tumor progression: Multiple tumor 
suppressor genes such as Nkx3.1, p27, PTEN and p53 are lost while many 
oncogenes such as MYC, Egr1 and Pim1 are activated during the progression of 
prostate cancer. Androgen signaling plays a pivotal role during prostate cancer 
progression. 
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       Table 3. Genes involved in prostate cancer initiation and progression 
 
Prostate Cancer stages 
 
Genes 
 
Comments 
 
 
Initiation & progression 
to carcinoma 
 
NKX3.1 
 
 
 
 
 
PTEN 
 
 
 
Rb, p27 
 
 
 
Myc 
 
 
 
ATBF1 
 
 
KLF5, KLF6 
 
 
E-cadherin, 
Integrins and c-
CAM 
 
Putative prostate tumor suppressor 
gene, 8p21 chromosomal region is 
deleted in prostate cancer, Mice 
lacking one or both alleles develop 
PIN lesions 
 
Frequent deletion of human gene 
10q23, Heterozygote mice develop 
hyperplasia and dysplasia 
 
Cell cycle regulatory proteins, Rb 
and p27 are often lost in prostate 
cancer 
 
Amplified in some cancers, co-
operates with RAS or other 
oncogenes 
 
16q22 region is frequently deleted 
in sporadic prostate cancers 
 
Haploid loss of 13q22 has been 
reported in prostate cancer  
 
Cell adhesion molecules, reduced 
expression in PIN and carcinoma 
 
Advanced carcinoma  & 
metastasis  
 
AR 
 
 
 
p53 
 
 
IGF1, TGFβ1, 
EGF 
 
Bcl2 
 
AR signaling plays crucial role, 
frequently mutated or amplified in 
prostate cancer 
 
Higher mutation rates in metastatic 
tumors than in primary cancer 
 
Growth factors, promote prostate 
epithelium growth and invasion 
 
Key regulator of apoptosis, 
overexpressed in androgen 
independent prostate tumors 
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 NKX3.1 
 
Nkx subfamily of homeodomain proteins: 
           Homeodomain proteins are a family of transcription factors characterized by a 
60-amino acid domain (homeodomain) that binds to certain regions of DNA. The 
homeodomain was first discovered in Drosophila and has been shown to play a 
significant role in determining the anterior-posterior axes of both invertebrates and 
vertebrates. Structurally, the homeodomain folds into three α helices, the latter two 
folding into a helix-turn-helix conformation which is characteristic of transcription 
factors that bind to DNA in the major groove of the double helix (Otting et al., 1990). 
The third helix is the recognition helix where amino acids make contact with the 
bases of the DNA (Figure 5).  
           Homeobox genes including NK subfamily genes are expressed either widely or 
in a tissue specific manner and are critical in specifying cell fates, development and 
differentiation in many species. Several studies in Drosophila have provided 
invaluable insights about functional relevance of NK homeobox genes. Particularly, 
NK-3 was identified as the bagpipe gene which is required for visceral mesoderm 
development (Kim and Nirenberg, 1989) while NK-2 (tinman) is required for the 
development of cardiac mesoderm (Azpiazu and Frasch, 1993). In amniotes, these 
functional relationships are well conserved.  
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Helix-turn-
helix    
 
Figure 5. Homeodomain (Helix-turn-helix) & DNA interactions: Note 
that homeodomain contains three α helices; two of them form a helix-
turn-helix conformation while the third helix (recognition helix) makes 
contact with the DNA (Adapted from book developmental biology, 6th 
edition by Scott Gilbert, Sinauer Associates, Inc publisher, 2000). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 11
 Nkx3.1 gene structure: 
            Human and mouse Nkx3.1 share ~ 60% overall amino acid homology and 
100% homology within the homeodomain. Mouse Nkx3.1 is located at chromosome 
14, syntenic with chromosome 8p in humans. The mouse Nkx3.1 gene (Figure 6) 
contains two coding exons, a short 5’ untranslated region (UTR) and long 3’ UTR 
which contains consensus sequences involved in post-transcriptional regulation 
(Sciavolino and Abate-Shen, 1998). The homeobox is located in the second exon 
which is identical to the homeodomain of NK-3. Nkx3.1 protein contains a TN motif 
(similar to eh1 domain identified in other homeoproteins) that interacts with Gro 
/TLE co-repressors and hence responsible for repressor activity of Nkx3.1. In 
humans, alternatively spliced forms of the Nkx3.1 gene have been reported which 
encode variants of the N-terminal coding region upstream of homeodomain (Korkmaz 
et al., 2000).   
 
 
Figure 6. Schematic representation of mouse Nkx3.1 genomic DNA and 
protein: Nkx3.1 gene contains two exons with short 5’ UTR and long 3’ UTR. 
Homeodomain is located in the second exon. TN motif is responsible for the co-
repressive activity. 
 
5’ 3’ 
Exon 1 Exon 2
Coding region Untranslated region (UTR)
N terminus C terminus
HomeodomainTN motif 
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 Transcriptional activities of Nkx3.1: 
             In general, homeodomain proteins can bind at DNA consensus sequences 
containing a “TAAT” core (Catron et al., 1993). Steadman identified “TAAGTA/G” 
as a consensus sequence for human NKX3.1 by binding site selection assays 
(Steadman et al., 2000). By electromobility shift assays (EMSA) Steadman 
demonstrated that NKX3.1 was preferentially bound to the TAAGTA consensus 
rather than the binding site for Nkx2.1 (CAAGTG) or Msx1 (TAATTG). However, it 
remains unclear whether Nkx3.1 protein binds to DNA as a monomer or dimer.  
             Interestingly, previous studies have provided evidence that Nkx3.1 has a 
wider transcriptional potential and that can act as a transcriptional repressor as well as 
an activator.  Most probably, this could be a promoter-specific process mediated 
through the differential recruitment of co-repressors / co-activators protein complexes 
containing Nkx3.1 at the specific promoter regions (Figure 7).  
Co-activator proteins
 
Figure 7. Schematic depiction of Nkx3.1 associated transcriptional activity: 
Nkx3.1 can form complex with either co-activator (top) or co-repressor 
(bottom) proteins on specific promoters causing gene activation (Gene X) or 
repression (Gene Y) respectively. 
Nkx3.1 
Gene X 
Co-repressor proteins 
Gene Y 
Nkx3.1 
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              Several in vitro studies indicate that Nkx3.1 acts as a transcriptional 
repressor. Steadman and colleagues demonstrated that human NKX3.1 can repress 
activity of a synthetic reporter containing a trimerized NKX3.1 consensus site 
upstream of a basal promoter (Steadman et al., 2000). These observations are 
consistent with the reports regarding Nkx3.2 which also behaved as a transcriptional 
repressor in transient transfection experiments in cell culture and retroviral expression 
studies in chick embryo (Murtaugh et al., 2001). Choi et al., demonstrated the 
interaction of NK-3 with Groucho and HIP1K (serine-threonine kinase) by co-
immunoprecipitation assays in Hela cells (Choi et al., 1999). He further proposed that 
Nk-3, Groucho and HIP1K proteins most likely exist in a complex with histone 
deacetylase HDAC1 constituting a single co-repressor complex (Choi et al., 1999). 
These studies indicate that Nkx3.1 represses transcriptional activity through 
recruitment of Gro/TLE co-repressor proteins. Chen et al., showed that transcriptional 
repressor activity of Nkx3.1 can be modulated by its interaction with PDEF (prostate-
derived Ets factor) proteins (Chen et al., 2002). By using a yeast-two hybrid 
approach, Chen and colleagues isolated PDEF as a novel Nkx3.1 interacting protein 
within a human cDNA expression library prepared from the prostate. They 
demonstrated that PDEF can increase transcriptional activity of the PSA promoter 
and that activity was repressed when Nkx3.1 was co-expressed with PDEF (Chen et 
al., 2002; Oettgen et al., 2000). Recently, Nkx3.1 has been shown to negatively 
regulate the transcriptional activity of Sp-family members in prostate-derived cells 
(Simmons and Horowitz, 2006).   
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             By contrast, some studies indicate that Nkx3.1 can act as a transcriptional 
activator. Carson and colleagues examined the expression of smooth muscle gamma-
actin (SMGA) as a marker of smooth muscle differentiation and found that Nkx3.1 
co-operates with serum response factor (SRF) in CV-1 fibroblasts (Carson et al., 
2000). Authors demonstrated that Nkx3.1 and SRF can synergistically activate 
SMGA reporter activity. This synergistic transactivation required adjacent Nkx3.1 
and SRF binding sites in the SMGA promoter. By using EMSA and footprinting 
analysis they further demonstrated that binding of Nkx3.1 to promoter DNA 
increased recruitment of SRF to the adjacent sites, resulting into increased 
transcriptional activity (Carson et al., 2000). This study also revealed that the C-
terminus of Nkx3.1 protein possess co-repressor activity in addition to a TN motif. 
The deletion of C-terminus resulted into ~ 15 fold increase in transcriptional activity 
of SMGA promoter in the absence of SRF suggesting that the C-terminus was 
responsible for co-repressor activity (Carson et al., 2000). Later studies (Filmore et 
al., 2002) also confirmed these findings supporting the notion that Nkx3.1 can act as a 
transcriptional activator in certain contexts.  
             Recent gene expression profiling analysis in Nkx3.1-mutant mice has 
identified a subset of positively regulated as well as a subset of negatively regulated 
genes by Nkx3.1 (Magee et al., 2003). Magee and colleagues compared Nkx3.1 target 
gene expression in Nkx3.1 wild type (+/+), heterozygous (+/-) and knockout (-/-) 
animals by utilizing a castration-testosterone replacement paradigm. They identified 
57 significantly altered genes; some of which were up-regulated while others were 
down-regulated in Nkx3.1-deficient mice compared to WT mice (Magee et al., 2003). 
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 Another independent gene expression profiling study identified several dysregulated 
(up-regulated/down-regulated) anti-oxidant and pro-oxidant enzymes in Nkx3.1- 
mutant mice (Ouyang et al., 2005). Taken together, these studies provide indirect 
evidence that Nkx3.1 can act as either a transcriptional activator or repressor, 
probably depending upon promoter context.  
 
Nkx3.1 and androgen receptor signaling: 
             The development, normal growth, and maintenance of the prostate gland are 
dependent on the function of androgens which act through activation of the androgen 
receptor (AR), a member of nuclear hormone receptor family of transcription factors. 
Following the pioneering work of Huggins and Hodges in the early 1940’s androgen 
ablation and anti-androgen therapy has become the cornerstone of treatment for 
prostate cancer patients. However, despite the initial response in ~ 80-85 % of 
patients, androgen-independent tumors eventually emerge, leaving hormone therapy 
and complete androgen blockade ineffective (Laufer et al., 1999). 
            Several lines of evidence support the concept that Nkx3.1 is an androgen 
regulated gene. Nkx3.1 mRNA levels decline precipitously after castration, prior to 
the post-castration atrophy (Bieberich et al., 1996). Nkx3.1 expression is detected 
only in androgen-responsive human prostate cancer cell line LNCaP but not in the 
androgen-receptor deficient prostate cancer cell lines such as DU145 and PC-3 (He et 
al., 1997; Prescott et al., 1998). Additionally, Nkx3.1 expression is induced with 
androgen treatment in a dose-dependent fashion in LNCaP cells. Prescott and 
colleagues further demonstrated that androgen-induced Nkx3.1 expression was 
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 directly through transcriptional up-regulation of the AR (Prescott et al., 1998). Later, 
Zhu and colleagues observed that Nkx3.1 expression was dramatically reduced by 
treatment with AR antagonist agents such as flufenamic acid (Zhu et al., 1999).  
             Interestingly, Lei and colleagues demonstrated that NKX3.1 can negatively 
regulate androgen receptor (Lei et al., 2006). Overexpression of NKX3.1 inhibited 
mRNA and protein levels of AR in cell cultures while increased AR levels were noted 
in NKX3.1 knockout mice prostates (Lei et al., 2006). Furthermore, Lei and 
colleagues were able to demonstrate that Nkx3.1 can repress AR transcription by 
luciferase reporter assays. In conclusion, this study provided evidence that NKX3.1 
and AR form a signaling feedback loop in which NKX3.1 is the negative modulator 
of AR and keeps AR level and AR-controlled pathways in check for normal prostate 
cell proliferation and survival (Lei et al., 2006).            
 
Nkx3.1 in prostate development: 
            Homeodomain proteins, including NK-family members play a critical role in 
development and differentiation (Krumlauf, 1994). During embryogenesis, Nkx3.1 is 
expressed in a wide range of tissues outside urogenital system including 
hippocampus, cerebral cortex, dorsal aorta, tongue, teeth, arteries of the kidney and 
the dorsal part of Rathke’s pouch (pituitary gland). However, Nkx3.1 null mutant 
mice do not show any phenotype in most of these nonurogenital tissues (Schneider et 
al., 2000; Sciavolino et al., 1997; Tanaka et al., 2000).  
            During organogenesis, formation of the prostate occurs through epithelial 
budding from the urogenital sinus. Nkx3.1 is expressed specifically in the prostate 
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 and bulbourethral glands but not in the seminal vesicles, bladder or urethra (Bhatia-
Gaur et al., 1999). Within the urogenital system, Nkx3.1 is first detected in lateral 
aspects of the urogenital sinus epithelium at 15.5 dpc, before prostate formation 
(Bhatia-Gaur et al., 1999). Nkx3.1 is expressed in the region from which prostatic 
epithelial buds emerge and subsequently prostatic buds undergo ductal branching and 
outgrowth into the surrounding mesenchyme. Nkx3.1 is expressed in all stages of 
differentiation of the prostate, before canalization of the prostatic duct, NKx3.1 is 
expressed uniformly in all epithelial cells but later its expression is restricted to the 
luminal epithelium.    
            Bhatia-Gaur further underscored the importance of Nkx3.1 in the development 
of prostate by using tissue recombination. Nkx3.1 was expressed specifically in tissue 
recombinants generated from prostate inducing mesenchyme (UGM) and bladder 
epithelium (BLE) in which Nkx3.1 is normally not expressed but not in tissue 
recombinants generated from bladder mesenchyme (BLM) and urogenital epithelium 
(UGE) which does normally express Nkx3.1(Bhatia-Gaur et al., 1999). Further, this 
study revealed that functional androgen receptor is not required for the initial Nkx3.1 
expression in the developing prostate; however it is required for the maintenance of 
Nkx3.1 expression throughout maturation.  
            Several studies have supported the requirement of Nkx3.1 in prostate ductal 
morphogenesis and epithelial differentiation. Nkx3.1 null mutant mice are viable and 
fertile suggesting that prostate is not absolute for fertility (Bhatia-Gaur et al., 1999; 
Schneider et al., 2000; Tanaka et al., 2000). Overall prostate size and weights of 
Nkx3.1 null mutant mice remained same when compared with the wild type mice. 
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 However, Nkx3.1 null prostates showed reduced ductal branching morphogenesis and 
decreased secretory protein production (Bhatia-Gaur et al., 1999). A similar 
phenotype was observed in the bulbourethral glands. In conclusion, these 
observations suggest that Nkx3.1 plays a role in early postnatal ductal morphogenesis 
as well as in the production of secretory proteins in mature prostate.     
 
Nkx3.1 in prostate cancer: 
            During the course of tumorigenesis, normal prostate epithelial cells can 
progress towards malignancy by acquiring a series of mutations (Figure 4). Prostate 
cancer like most of other cancers arises from a precursor lesion called as prostatic 
epithelial neoplasia (PIN). Upon additional genetic hits, PIN lesions often progress to 
locally invasive disease and ultimately metastasis. Each stage of prostate cancer is 
associated with chromosomal alterations and shows characteristic morphological and 
histological changes.  
            Several chromosomal regions (8p21, 10q and 12q) are commonly lost in 
human prostate cancer suggesting involvement of many tumor suppressor genes in 
prostate tumor initiation and progression. In particular, loss of heterozygosity (LOH) 
at human chromosome 8p21-22 is most commonly described genetic alteration in 
prostate cancer (Bott et al., 2005). NKX3.1 is the leading candidate gene located in 
the human 8p21 region (Dong, 2001; Voeller et al., 1997). PTEN and p27kip1 are the 
other candidates at regions 10q and 12q respectively (Abate-Shen and Shen, 2000; Di 
Cristofano and Pandolfi, 2000). PTEN and p27kip1 tumor suppressors are lost in many 
cancers while loss of NKX3.1 is specific to prostate cancer.    
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             Several studies have been conducted to identify mutations in the coding 
region of Nkx3.1 (Kim et al., 2002; Ornstein et al., 2001; Voeller et al., 1997; Xu et 
al., 2000). No mutations were found however, a polymorphism at nucleotide position 
154 (C154T) was reported by several groups (Voeller et al., 1997; Xu et al., 2000). 
Recently, Zheng and colleagues resequenced the Nkx3.1 coding and regulatory 
regions of 159 probands of hereditary prostate cancer families and identified 21 germ-
line variants, including the previously described C154T polymorphism (Zheng et al., 
2006). This study showed that the germ-line variants were significantly linked to the 
risk of having hereditary prostate cancer. Nevertheless, prostate cancer associated 
somatic mutations have yet to be reported.   
            Apart from mutational analysis, several mRNA and protein expression studies 
for Nkx3.1 have also been performed (Asatiani et al., 2005; Bowen et al., 2000; 
Korkmaz et al., 2004; Xu et al., 2000). An initial NKX3.1 mRNA expression analysis 
by Xu and colleagues reported increased expression of NKX3.1 in prostate cancers 
compared with adjacent normal tissue (Xu et al., 2000). However, Bowen and 
colleagues (Bowen et al., 2000) examined NKX3.1 protein expression in tumor 
samples with different histological grades and found that NKX3.1 protein was lost in 
PIN lesions (~20%), invasive (~ 40%) and metastatic (~75%) prostate tumor tissues 
but not in benign prostatic hyperplasia (BPH) lesions (5%). This study also revealed 
that loss of NKX3.1 protein expression was strongly correlated with prostate tumor 
progression. These findings were further supported by another study in which the 
authors found a significant loss of NKX3.1 expression in preinvasive and invasive 
tumor tissues compared to normal surrounding prostate tissue (Asatiani et al., 2005). 
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             Along with the above mentioned human studies, there are several lines of 
evidence that support the critical role of Nkx3.1 as a tumor suppressor in prostate. 
First and foremost is the fact that Nkx3.1-mutant mice develop PIN lesions that 
closely resemble human PIN lesions (Abdulkadir et al., 2002; Bhatia-Gaur et al., 
1999). In mice, deletion of the Nkx3.1 gene leads to developmental defects in the 
prostate gland, including defects in ductal branching morphogenesis, prostatic 
secretions and epithelial hyperplasia and dysplasia (Bhatia-Gaur et al., 1999; 
Schneider et al., 2000; Tanaka et al., 2000). However, because of severe 
developmental defects these Nkx3.1 transgenic models were not ideal to explore the 
precise role of Nkx3.1 in prostate cancer. Abdulkadir et al (2002) generated a 
conditional Nkx3.1-deficient mouse model by using Cre- and loxP mediated 
recombination to delete Nkx3.1 gene in the prostates of adult transgenic mice. 
Conditional deletion of one or both alleles of Nkx3.1 resulted the development of PIN 
lesions which showed histological resemblance to PIN lesions from human patients 
(Abdulkadir et al., 2002). Notably, Nkx3.1-mutant mice develop PIN lesions but do 
not progress to carcinoma. Kim and colleagues successfully employed serial passage 
of tissue recombination to promote PIN lesions to progressive neoplastic lesions (Kim 
et al., 2002). 
            Although loss of Nkx3.1 alone is not sufficient for the development of 
prostate cancer, Nkx3.1 can cooperate with other tumor suppressor genes to suppress 
prostate tumor formation. In particular, Nkx3.1 has been shown to cooperate with 
PTEN which is also lost in human prostate cancer (Dong, 2001; Kim et al., 2002). 
The compound Nkx3.1; Pten mutant mice develop severe high-grade PIN (HGPIN) 
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 lesions by 6 months of age than single mutants suggesting strong cooperativity 
between Nkx3.1 and Pten (Kim et al., 2002). This cooperativity between Nkx3.1 and 
Pten has been shown to be mediated through the PI3Kinase-Akt signaling pathway, 
whose activation occurs because of loss of function of Pten (Cantley, 2002; Di 
Cristofano and Pandolfi, 2000). Nkx3.1 can also cooperate with cyclin-dependent 
kinase inhibitor p27kip1 to suppress prostate tumorigenesis (Gary et al., 2004). 
Nkx3.1; p27kip1 double nullizygous mice developed extensive PIN lesions with 
increased incidence compared to Nkx3.1 or p27kip1 single nullizygous mice. 
Interestingly, authors observed the most cooperativity with complete loss of at least 
one of the two genes because compound heterozygous mice exhibited a similar 
phenotype (not more severe) to single heterozygous mutants (Gary et al., 2004). 
There is also evidence that tumor suppressor gene Nkx3.1 and the oncogene Myc can 
cooperate and that loss of Nkx3.1 along with gain of Myc may play critical roles in 
prostate tumor progression (Ellwood-Yen et al., 2003).  
 
HAPLOINSUFFICIENCY 
 
Origin and definition:  
            In diploid organisms, two functional copies of all genes are present, with the 
exception of genes on the X and Y chromosomes and imprinted genes. A single 
normal allele is often sufficient to maintain the normal function of a cell; however, 
some genes or gene functions are very sensitive to gene dosage level. 
Haploinsufficiency (HI) represents that special circumstance in which one working 
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 allele is insufficient to support normal cellular function. Curt Stern first applied the 
term ‘haploinsufficiency’ in his study of dosage effects on the cubitus interruptus 
allele of Drosophila (Stern and Schaeffer, 1943). Despite the long history of 
haploinsufficiency in genetics, translation of this concept to tumor suppressor genes 
has been slow due to the lack of experimental evidence as well as a perceived conflict 
between concepts of haploinsufficiency and the original Knudson two hit hypothesis.                  
            During the course of cancer development, a normal cell can progress towards 
malignancy by acquiring a series of mutations. These include mutations that activate 
proto-oncogenes (gain of function) or that inactivate recessive tumor suppressor 
genes (loss of function). According to the prevailing paradigm for tumor suppressor 
gene function, Knudson’s two-hit model (Figure 8A), tumor suppressor genes are 
recessive and both alleles must be inactivated for tumorigenesis (Knudson, 1985). 
However, several recent studies have challenged the generality of this model and 
supported evidence for haploinsufficiency as another model (Figure 8B). 
Haploinsufficient tumor suppressor genes lead to accelerated tumorigenesis without 
the requirement for inherited mutation of one allele.  Haploinsufficiency can be 
detrimental to various regulatory processes in cell biology such as cell cycle 
regulation, apoptosis and DNA synthesis or repair (Cook et al., 1998) and hence, it 
plays a significant role in many human disorders including cancer and developmental 
defects (Seidman and Seidman, 2002).   
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Models of tumor suppression 
A) Classic two-hit tumor suppression model
Normal cell
B) Haploinsufficient tumor suppression model
Cancer cell
 
 
Figure 8. Models of tumor suppressor genetics: A) Classic two-hit model for tumor 
suppression implies that both alleles must be inactivated for tumorigenesis. B) 
Haploinsufficient tumor suppression model implies that even a loss of single allele is 
sufficient for tumorigenesis. 
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 Haploinsufficiency and tumorigenesis: 
            The incidence of human cancer depends upon the number and frequency of 
rate limiting mutations and the size of the target cell population (Quon and Berns, 
2001). It is estimated that 4-8 rate limiting mutations are required for the development 
of most human cancers. With these considerations, cancer is expected to arise at a low 
frequency (~1 in 10-21 cells). However, the odds for developing cancer during one’s 
lifetime (~1 in 3) are much higher (Quon and Berns, 2001). Hence, there must be 
additional factors which increase the human cancer risk. These include epigenetic 
changes such as promoter hypermethylation that can silence tumor suppressor genes 
or genomic instability that can increase the overall mutation rate (Cahill et al., 1999; 
Jaenisch and Bird, 2003). Haploinsufficiency at tumor suppressor loci has certainly 
been considered as one of the phenomena that increase overall cancer risk, with 
different tumor suppressor genes showing varying degrees of haploinsufficiency 
(Cook and McCaw, 2000; Quon and Berns, 2001).  
            Several tumor suppressor genes including p53 (Trp53), p27kip1(Cdkn1b), 
Dmp1 and Nkx3.1 encode transcription factors that demonstrate haploinsufficiency 
(Abdulkadir et al., 2002; Bhatia-Gaur et al., 1999; Cook and McCaw, 2000; Fero et 
al., 1998; Inoue et al., 2001; Venkatachalam et al., 1998). The first definitive 
evidence for haploinsufficiency for tumor suppression was provided for p27kip1 (Fero 
et al., 1998). Mice homozygous for loss-of-function mutations in p27kip1 suffer from 
multi-organ hyperplasia. Fero demonstrated that p27kip1 heterozygous mice developed 
tumor similar to p27kip1 homozygous with a penetrance of 32 % (Fero et al., 1998). 
Further, when treated with a carcinogen or irradiation, p27kip1 heterozygous mice 
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 developed more tumors than wild type mice bur fewer than homozygous mutants. 
Notably, the wild type allele of p27kip1 was expressed in these tumors, suggesting 
haploinsufficiency for p27kip1 (Fero et al., 1998).  
           Venkatachalam et al (1998), analyzed mice carrying one mutant allele of p53. 
Almost, all p53+/- mice developed tumors or died by 2 years of age whereas in wild-
type mice only 20% mice died or developed tumors. The wild-type p53 allele was 
retained in many tumors occurring in p53+/- mice (Venkatachalam et al., 1998). This 
study provided supporting evidence for haploinsufficiency for p53 including the facts 
that p53 transcripts were unmutated after sequencing, intact p53 protein expression 
was observed, p53 dependent transcriptional responses were intact, and lastly, 
irradiation induced increase in apoptosis was observed in p53+/- mice but not in p53-/- 
mice (Venkatachalam et al., 1998).  Recently, p21 one of the key p53 target genes has 
been found to be haploinsufficient for tumor development (Jackson et al., 2003). 
Mice heterozygous and homozygous for a mutation of p21 were more prone to tumor 
formation after irradiation and tumors from heterozygous mice retained the wild-type 
allele of p21. Intriguingly, tumors from p21 homozygous null mice metastasized 
while those from heterozygous did not suggesting a less severe phenotype and 
haploinsuffciency for p21 (Jackson et al., 2003).   
            Inoue et al (2001) investigated the effects of Dmp1 haploinsufficiency in 
Dmp1 mutant mice. Dmp1 is a transcription factor which induces Arf gene 
transcription by binding to its promoter. Both homozygous and heterozygous Dmp1 
mutant mice were significantly more tumor prone than wild-type mice both 
spontaneously and after irradiation (Inoue et al., 2001). Furthermore, tumors in 
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 Dmp1+/- mice retained expression of the wild-type allele again providing evidence for 
haploinsufficiency.  
           Several studies have shown that haploid deletion of tumor suppressor gene 
Nkx3.1 is frequently associated with prostate cancer and prostatic intraepithelial 
neoplasia (PIN) (Bova et al., 1993; He et al., 1997; Macoska et al., 1995). Consistent 
with the observations of LOH in human PIN lesions and prostate cancer, mice in 
which a single Nkx3.1 allele is conditionally deleted in adulthood developed prostatic 
hyperplasia and PIN lesions (Abdulkadir et al., 2002). Interestingly, the hyperplastic 
lesions of these mice as well as those of conventional heterozygous mice retained 
Nkx3.1 protein expression from the remaining wild type allele providing evidence for 
haploinsufficiency for Nkx3.1 (Abdulkadir et al., 2002; Bhatia-Gaur et al., 1999). 
Magee et al (2003) investigated the molecular mechanism of haploinsufficiency in 
Nkx3.1 heterozygous mice and proposed a model of dosage sensitive and stochastic 
Nkx3.1 target gene regulation as a potential mechanism (Magee et al., 2003). Dosage-
sensitive and stochastic Nkx3.1 target gene regulation is discussed later in a separate 
section.  
           Many other genes also demonstrate haploinsufficiency in tumorigenesis 
including genes involved in cell cycle regulation and maintenance of genomic 
stability (Santarosa and Ashworth, 2004) (Table 4).    
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 Table 4. Genes that demonstrate haploinsufficiency in tumorigenesis 
Gene Function Associated Cancer syndrome 
 
APC 
 
Arf 
ATM 
BRCA1/2 
Dmp1 
H2AX 
MAD2 
MSH2 
NF1 
Nkx3.1 
P27 
P53 
 
PTEN 
Rb 
SMAD4 
TGFβ1 
 
Regulation of β-catenin, 
microtubule binding 
 
Stabilizes P53 
 
DNA integrity/repair 
 
DNA repair/transcription 
 
Transcription factor 
 
DNA repair 
 
Mitotic checkpoint 
 
DNA mismatch repair 
 
GAP for p21 ras proteins 
 
Transcription factor 
 
Cell cycle control checkpoint 
 
Transcription factor, 
apoptosis, response to DNA 
damage 
 
Dual-specificity phosphatase 
 
Modulation of cell cycle 
 
Signal transduction 
 
Growth Factor 
 
Colorectal cancer, FAP 
 
 
Melanoma 
 
Ataxia telangectasia 
 
Breast, ovarian other cancers 
 
Gastrointestinal cancer 
 
 
 
 
 
HNPCC, endometrial cancers 
 
Neurofibromatosis type I 
 
Prostate cancer 
 
AML 
 
Soft tissue sarcoma, 
osteosarcoma, Li-Fraumeni 
Syndrome 
 
Breast, thyroid, endometrial Ca
 
Retinoblastoma, osteosarcoma 
 
Pancreatic, colorectal cancer 
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 Haploinsufficiency and developmental defects: 
            Haploinsufficiency of transcription factors may cause some developmental 
anomalies especially if the transcription factor is critical for development or 
organogenesis. Haploinsufficiency of members of several gene families including 
Homeobox genes, T-box genes, HMG box genes, Paired box genes and Zinc finger 
genes produce more than 30 human syndromes which are summarized in Table 5 
(Seidman and Seidman, 2002).  
Table 5. Transcription factor haploinsufficiency and developmental syndromes  
 
Gene Class Developmental defects / syndromes 
PITX3 
 
NKX2.5 
 
NKX2.1 
SHOX 
 
Homeobox 
 
 
- Rieger syndrome (Malformation of anterior 
chambers of eye, muscular dystrophy 
- Heart defects including atrial septal defects 
and atrioventricular nodal defects 
- Choreoathetosis, pulmonary dysfunction 
- Deformities of radius, ulna and carpal bones 
TBX1 
TBX5 
 
TBX3 
 
 
T-box 
 
- DiGeorge syndrome 
- Holt-Oram syndrome (Atrial septal defect 
and hand anomalies) 
- Ulnar-mammary syndrome (delayed 
puberty, obesity, ulnar ray defects) 
 
HFN1B / 1A 
 
SOX 9/ 10 
 
HMG box 
 
 
- Familial glomerulocystic kidney disease and 
diabetes (maturity onset diabetes in young) 
- Deafness, aganglionic megacolon, dwarfism 
PAX2 
PAX8 
PAX6 
 
Paired box - Renal and optic coloboma 
- thyroid dysgenesis 
- Aniridia type II 
WT1 
 
GATA3 
 
 
Zn finger - WAGR syndrome (Wilms tumor-aniridia-
genitourinary-mental retardation) 
- Hypoparathyroidism, sensorineural deafness 
renal dysplasia   
FOXC2 
FOXC1 
 
Forkhead - Lymphedema-distichiasis syndrome 
- Defects of eye, glaucoma 
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 HAPLOINSUFFICIENCY AT THE NKX3.1 LOCUS: DOSAGE-SENSITIVE, 
STOCHASTIC GENE REGULATION   
 
Nkx3.1 regulates cell cycle exit during luminal cell regeneration: 
            Nkx3.1-deficient mice (Nkx3.1+/- and Nkx3.1-/-) develop prostatic hyperplasia 
and PIN lesions over time which mimic the PIN lesions in humans (Abdulkadir et al., 
2002; Bhatia-Gaur et al., 1999). These observations suggested that Nkx3.1 may 
establish or maintain luminal epithelia in a growth-arrested state and that loss of one 
or both alleles of Nkx3.1 may lead to proliferation of luminal cells. Magee et al., 
(2003) further extended these observations and analyzed the dosage-sensitive 
phenotype of Nkx3.1-deficient mice by utilizing the castration-testosterone 
replacement (TR) model as shown in figure 9 (Magee et al., 2003).  
            Magee and colleagues castrated Nkx3.1+/+, Nkx3.1+/- and Nkx3.1-/- mice (8 
weeks old), subsequently implanted sustained release testosterone pellets for 14 days 
after castration and analyzed mRNA and protein expression pattern of Nkx3.1 and 
Ki67 as a luminal cells proliferation marker (Magee et al., 2003). The Ki67 profiles 
revealed that Nkx3.1-/- and Nkx3.1+/- (lesser extent) luminal epithelium cells failed to 
exit the transient proliferation state. In contrast to wild type luminal cells, Nkx3.1-/- 
and Nkx3.1+/- luminal epithelium cells were proliferating for at least one week after 
testosterone replacement. This extended proliferation resulted into the luminal 
hyperplasia which was evident in Nkx3.1-/- prostates by 14 days post-TR (Magee et 
al., 2003). In spite of the delay in terminal differentiation, Nkx3.1-deficient cells 
ultimately did undergo growth arrest following TR (Magee et al., 2003).   
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Castration Testosterone replacement
14-14 0 3 7
Differentiation / Growth arrestApoptosis Proliferation
 
 
Figure 9. Schematic of Castration-testosterone replacement model for prostate 
growth and differentiation: After castration Nkx3.1-mutant mice prostates 
undergo apoptosis in 14 days. After testosterone treatment, prostates cells undergo 
proliferation (3-7 days), differentiation (7-14 days) and ultimately growth arrest 
(Adapted from Magee et al., 2003). 
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 Dosage sensitivity of Nkx3.1 target genes: 
             Androgens play a pivotal role in the growth and maintenance of the prostate 
and perturbations in androgen signaling may lead to the development of prostate 
cancer. Magee et al., (2003) provided evidence that Nkx3.1-deficient luminal 
epithelial cells undergo an extended phase of transient proliferation. This observation 
implied that Nkx3.1 and androgens cooperatively regulate gene expression during 
prostate regeneration. Magee and colleagues performed gene expression profiling 
studies on Nkx3.1+/+, Nkx3.1+/- and Nkx3.1-/- mice after castration-TR and identified 
57 genes that were significantly altered in Nkx3.1-/- mice compared to wild type mice. 
Interestingly, hierarchical clustering of Nkx3.1 target genes identified discrete 
clusters of positively (activated) and negatively (repressed) regulated genes by 
Nkx3.1. Positively regulated genes (e.g., probasin, intelectin) showed much lower 
expression in Nkx3.1+/- and Nkx3.1-/- mice compared to the expression in wild type 
mice whereas negatively regulated genes (e.g., angiopoietin 2, sushi-repeat protein X) 
showed higher expression in Nkx3.1+/- and Nkx3.1-/- mice as shown in Figure 10 
(Magee et al., 2003). Notably, the expression of all Nkx3.1 regulated genes was 
influenced by androgen status supporting the notion that Nkx3.1 is an androgen target 
and its expression is regulated by androgens. 
             Upon further analysis, Magee and colleagues observed a spectrum of dosage-
sensitivity among the Nkx3.1-activated genes (Figure 10A), genes like Probasin and 
Riken clone appeared relatively insensitive to the Nkx3.1 dosage (similar expression 
levels were observed in Nkx3.1+/+ and Nkx3.1+/- mice) while genes like Intelectin and 
Pdzk1 appeared highly dosage-sensitive even to the loss of single allele of Nkx3.1 
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 (Note that expression levels in Nkx3.1+/- mice were similar to the levels in Nkx3.1-/- 
mice). 
 
A) Nkx3.1-activated genes 
 
Dosage-insensitive Intermediate Dosage-sensitive More Dosage-sensitive 
B) Nkx3.1-repressed genes 
 
Figure 10. Androgen regulated Nkx3.1 target gene qRT-PCR expression profile: 
A) Nkx3.1-activated genes show a spectrum of dosage-sensitivities. Genes such as 
Probasin and Riken clone are relatively insensitive while genes such as Intelectin and 
Pdzk1 are more sensitive to the Nkx3.1 dosage.  B) Nkx3.1-repressed genes such as 
Angiopoietin 2 and Elafin-like II do not show dosage-sensitivity. (Adapted and 
modified from Magee et al., 2003) 
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 Stochastic expression of Nkx3.1-activated target genes: 
             Transcriptional regulation is very complex and two types of transcriptional 
models are commonly accepted (Figure 11). The first transcriptional model is the 
most popular view and implies that transcription is a graded process with promoter 
activity directly proportional to the levels of one or more transcription factors (e.g., 
promoter activity increases uniformly in all cells in response to increasing levels of 
transcription factor dosage). This model is commonly referred as the “rheostatic” or 
“rate” or “graded” model (Figure 11A).  
             As opposed to the graded model, there is a lot of supporting evidence for the 
“stochastic” or “binary” or “probabilistic” model for transcriptional activation 
(Fiering et al., 2000). According to this model, genes exist in either “on” or “off” 
state and transcription factor dosage regulates the probability of a gene occupying 
either active or inactive state as shown in Figure 11B (Fiering et al., 2000). Numerous 
studies have demonstrated that cells within a homogeneous population do not always 
respond with a uniform induction of gene expression even though they are subjected 
to identical stimuli. The expression of ApoB in the avian liver was found to be 
responsive to estrogen and this induction was achieved by recruitment of hepatocytes 
from a silent to an expression state (Lin et al., 1986). Van Roon et al (1989) observed 
that induction of different enzymes involved in the ornithine cycle such as carbamoyl 
synthetase, phosphoenolpyruvate carboxykinase and arginase by glucocorticoids was 
stochastic in cultures of fetal hepatocytes (van Roon et al., 1989). The expression of 
various serum proteins including albumin appeared heterogeneous in hepatocytes and 
further, hepatocytes were recruited to the expressing pool in a stochastic manner upon 
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 activation (Michaelson, 1993). Cytokine induction by antigen presentation in clonal 
populations of T cells was also reported as a stochastic process (Bucy et al., 1994). 
Newlands and colleagues examined expression of both muscle specific transgenes 
and endogenous genes in the individual nuclei of multinuclear myofibers and found 
that the genes were expressed in only subset of nuclei even though all were part of a 
single cell providing additional evidence for the stochastic regulation (Newlands et 
al., 1998). Lastly, Riviere and colleagues demonstrated that individual alleles of IL-4 
gene can be regulated independently and stochastically within the same nucleus 
(Riviere et al., 1998).   
Models of gene activation 
B) Binary/Probabilistic A) Graded Response/Rheostat  
Model Model 
Gene Activation
 
Figure 11. Models of transcriptional regulation: A) Graded response(Rheostat)model 
implies that promoter activity is directly proportional to the levels of one or more 
transcription factors supporting the uniform expression of a given gene at a cellular level  
B) Stochastic (probabilistic) model implies that genes exist in either “on” or “off” state 
and transcription factor dosage determines the probability of a given gene to occupy 
either state supporting the non-uniform expression pattern at a cellular level.  
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              Although, most experimental data are consistent with either model of gene 
activation; the two models are not mutually exclusive and hence, both forms of 
regulation might be possible. To distinguish whether Nkx3.1 target genes are 
activated by a graded model or stochastic model, Magee and colleagues performed in 
situ hybridization experiments in Nkx3.1-mutant prostates for the two representative 
activated genes probasin (dosage-insensitive target) and intelectin (dosage-sensitive 
target). In situ hybridization analysis revealed the stochastic (non-uniform) expression 
patterns for both probasin and intelectin (Figure 12). Probasin was uniformly 
expressed in wild type and Nkx3.1+/- prostates, but Nkx3.1-/- prostates showed a 
heterogeneous population with probasin expressing and non-expressing cells (Magee 
et al., 2003). Similarly, in the case of intelectin wild type prostates, heterogeneous 
expression profile was observed while no expression was observed in Nkx3.1+/- and 
Nkx3.1-/- prostates (Figure 12). Notably, Nkx3.1 protein expression in wild type and 
heterozygous prostates showed a uniform pattern.  
             Based on these observations, Nkx3.1-activated target genes seem to be 
regulated by stochastic or binary promoters wherein Nkx3.1 gene dosage mainly 
influence the stochastic probability of either “on” or “off” state of target gene rather 
than the absolute level of target gene activity in a given cell.     
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Stochastic expression of Nkx3.1 target genes 
 
 
Figure 12. Stochastic expression pattern of Nkx3.1 target genes by in situ 
hybridization: Note the mosaic (heterogeneous) pattern of expression for intelectin in 
wild type and probasin in Nkx3.1-/- prostates. Note the arrow pointing cells do not 
express either intelectin or probasin (Adapted and modified from Magee et al., 2003). 
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 Model of Nkx3.1 haploinsufficiency in prostate cancer:  
             The dosage sensitive and stochastic nature of Nkx3.1 target genes readily 
explains the null phenotype in some heterozygous cells and molecular mechanisms 
underlying the haploinsufficiency in prostate tumor initiation. Consistent with the 
stochastic model, Magee and colleagues observed that Nkx3.1 dosage affects the 
probability that a given target gene exists in either an “on” or “off” state. They 
proposed a mechanism wherein at the point of tumor initiation; loss of single allele of 
Nkx3.1 would enhance the probability of complete inactivation of a dosage-sensitive 
target gene in luminal epithelial cells in a stochastic manner, in turn extending the 
proliferative phase of luminal amplifying cells. These cells would undergo clonal 
expansion and provide a larger target cell population which could further acquire 
additional genetic mutations during prostate tumor progression (Magee et al., 2003).   
  
Model of haploinsufficiency
 
Figure 13. A model of haploinsufficiency in prostate tumor initiation: A) Loss of 
first allele of tumor suppressor gene (TSG) such as Nkx3.1 stochastically inactivates 
target gene expression (Black lines) in a subset of heterozygous cells. B) These cells 
would clonally expand and provide a larger reservoir of cells for additional mutations 
during tumorigenesis  
 
+/+ +/+ +/+ +/+ 
A. Loss of first  
+/-+/+ +/++/- +/-+/- +/+ +/+
    allele of TSG
B. Selective growth 
       advantage
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 NOISE (STOCHASTICITY) IN GENE EXPRESSION 
 
Definition: 
             Genetically identical cells or organisms exhibit remarkable diversity even 
though they have identical histories of environmental exposure. Noise or variation in 
the process of gene expression often contributes to such a phenotypic variability 
(Raser and O'Shea, 2005). ‘Noise’ in gene expression can be defined as the measured 
level of variation in gene expression among identical population of cells. 
Mathematically noise can be calculated as the ratio of standard deviation (SD) to the 
mean of population.  
 
Sources and measurement of noise: 
             Gene expression often involves a series of single molecule events and as each 
of these molecular events is subject to fluctuations, gene expression is best viewed as 
a stochastic process (Rao et al., 2002). Four potential sources of variation in gene 
expression have been proposed: 1) The inherent stochasticity of biochemical 
processes; 2) differences in the internal states of a population of cells such as cell 
cycle progression; 3) environmental differences; 4) random or directed genetic 
mutations (Raser and O'Shea, 2005).  
             Recently, scientists have developed a two-reporter system with fluorescent 
protein (GFP) variants which allows the quantification of protein levels and detection 
of noise in living cells. This method involves quantification of expression of two 
equivalent, independent gene reporters placed in the same cell so that one can 
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 distinguish between two types of noises: ‘intrinsic noise’ referring to sources that 
create differences between two reporters within the same cell and ‘extrinsic noise’, 
referring to sources that affect two reporters equally in any given cell but create 
differences between two cells (Figure 14).      
 
 
 
Figure 14. Noise in gene expression: Noise can be divided as intrinsic noise which 
occurs because of stochastic events during the process of gene expression or extrinsic 
noise which could be global affecting expression of all genes or gene /pathway specific. 
          
Noise analysis: 
            To study the origin of noise in gene expression, McAdams and Arkin first 
proposed a stochastic model of gene expression in prokaryotes which implied that 
proteins are produced in random bursts and protein translation can amplify 
transcriptional noise (McAdams and Arkin, 1997). Numerous other models have 
Intrinsic noise Extrinsic noise 
Differences between cells, local environment 
changes, differences in the concentration or 
activity of any factor that affects gene expression 
Global noise Gene or pathway-
specific noise 
Noise in gene expression
Stochastic events during the process of gene 
expression (e.g. promoter-binding to 
mRNA translation to protein degradation) 
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 further validated these findings by analyzing the mechanisms that contribute the 
generation of noise in gene expression (Kierzek et al., 2001; Thattai and van 
Oudenaarden, 2001). As an experimental verification, van Oude-naarden and 
colleagues studied expression of GFP markers to quantify noise in the prokaryote 
Bacillus subtilis and provided evidence that transcription is the source for most of the 
noise during translation (Ozbudak et al., 2002).   
            Elowitz et al (2002) employed two-reporter method to detect noise in gene 
expression in Escherichia coli which quantified cyan and yellow fluorescent protein 
levels expressed from identical promoters on the same prokaryotic chromosome. 
Elowitz and colleagues identified noise in protein levels in a clonal population of E. 
coli due to the stochastic nature of gene expression (Elowitz et al., 2002). 
            Raser and O’Shea measured noise in cells of budding yeast, Saccharomyces 
cerevisiae (Raser and O'Shea, 2004). These studies revealed that the noise in protein 
level was due to the slow interconversion between inactive and active promoter states 
(Figure 15) and stochastic chromatin remodeling events (Raser and O'Shea, 2004). 
These studies further demonstrated that extrinsic noise was the predominant form of 
the detectable noise and it was global in nature (Raser and O'Shea, 2004). 
 
Noise in biology: 
             Noise is not limited to gene expression but has a wider relevance in biology. 
Any individual in a population of living organisms is unique and indeed the genetic 
and environmental histories contribute to the cellular variability. Noise has many 
roles in biological functions which include generation of errors during DNA 
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 replication leading to mutations and evolution, noise-driven divergence of cell fates, 
noise-induced amplification of signals and the maintenance of the quantitative 
individuality of cells (Rao et al., 2002). Hence, multiple cellular processes such as 
ion-channel gating, neural firing and cytoskeleton dynamics are influenced by noise 
(Allen and Stevens, 1994; van Oudenaarden and Theriot, 1999; White et al., 2000).         
 
Significance of noise: 
             Noise in gene expression may confer a fitness advantage or disadvantage. 
Intrinsic noise can produce fluctuations in the relative expression of two alleles of the 
same gene in a heterozygote, resulting in cells that express no allele, either individual 
allele or both alleles (phenomenon of hybrid vigor). Intrinsic noise plays a role in 
haploinsufficiency where increased levels of noise leads to stochastic inactivation of 
target genes in a subset of heterozygous cells, in turn promoting tumorigenesis 
(Magee et al., 2003).  
             Furthermore, stochasticity in gene expression may play a role in 
differentiation in multicellular organisms or in survival in fluctuating environments 
for unicellular organisms such as during the lambda phage lysis-lysogeny switch and 
in mammalian olfactory neuronal receptor choice (Arkin et al., 1998; Serizawa et al., 
2003).  
             Finally, noise can be advantageous if environmental conditions become more 
stressful, as noisy population may produce some members that could be better 
adapted to the new environment. In conclusion, stochasticity in gene expression is not 
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 necessarily an obstacle for cellular behavior, but it may be an evolvable source of 
population diversity for better adaptation (Raser and O'Shea, 2004).  
 
Control of noise: 
             Various mechanisms have been proposed that control noise in biological 
systems. Several lines of evidence suggest that control of noise is under evolutionary 
pressure. The simplest and most common noise attenuating regulatory mechanism is 
negative feedback. Becksei and colleagues constructed a negative feedback module in 
E. coli and demonstrated that variation in expression of GFP was reduced by the 
addition of the negative feedback using the tetracycline repressor (Becskei and 
Serrano, 2000).  
             Another type of feedback is integral feedback which is a part of negative 
feedback that uses internal memory states to attenuate noise. This type of mechanism 
is suggested in the case of bacterial chemotaxis in which integral feedback measures 
temporal changes in chemical concentrations rather than steady-state changes 
resulting into biased motion towards an attractant and thus early adaptation (Yi et al., 
2000).            
             Gene dosage and parallel cascades reduce noise by increasing the likelihood 
of gene expression or establishing consensus from multiple signals (Cook et al., 1998; 
McAdams and Arkin, 1999). Other mechanisms including regulatory checkpoints in 
cell cycle events (Hartwell and Weinert, 1989) and kinetic proofreading in protein 
translation to correct possible errors (Rodnina and Wintermeyer, 2001) have also 
been studied. 
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              Experimental evidence from Bacillus subtilis suggest that frequent 
transcription followed by inefficient translation results in lower noise in protein levels 
compared to infrequent transcription followed by efficient translation (Ozbudak et al., 
2002). Similarly, studies from Raser and O’Shea in budding yeast suggest that 
frequent promoter activation events followed by inefficient transcription results in 
lower noise in mRNA levels than infrequent promoter fluctuations followed by 
efficient transcription as shown in Figure 15 (Raser and O'Shea, 2004). These studies 
underscore the importance of stochastic chromatin remodeling events in the 
generation of noise in gene expression.              
 
Control of noise in gene expression
Inactive promoter 
Frequent Infrequent 
 promoter transition  promoter transition 
Active promoter 
Inefficient transcriptionEfficient transcription
Transcription 
Noise
 
 
 
Figure 15. Control of noise in gene expression: Inactive to active promoter transitions 
and stochastic chromatin remodeling events play role in the control of noise. Frequent 
promoter transitions followed by inefficient transcription can attenuate noise whereas 
infrequent or slow promoter transitions followed by efficient transcription may increase 
noise in gene expression (Adapted and modified from Raser et al., 2005). 
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 CHROMATIN REMODELING  
 
Epigenetics: 
             ‘Epigenetic’ is the term used to describe mitotically and meiotically heritable 
states of gene expression that are not due to the changes in DNA sequence (Bird, 
2002). Epigenetic changes are implicated in many aspects of cell biology (Figure 16) 
including cancer development, X-inactivation, genomic imprinting, position-effect 
variegation and developmental anomalies (Yoo and Jones, 2006). Two of the most 
studied epigenetic phenomena are DNA methylation and covalent modifications of 
histones. 
Epigenetics in human biology 
Cell cycle  
progression 
DNA replication 
 
 
Figure 16. Epigenetics in human biology: Epigenetic alterations play a significant role 
in various key regulatory processes in cell biology such as cell cycle progression, DNA 
replication and repair, germline silencing, imprinting, genomic stability and stem cell 
divisions.  
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 DNA methylation: 
             DNA methylation is one of the best-known epigenetic signals. DNA is 
methylated by DNA methyltransferases (DNMTs) at the 5-position (C5) of the 
cytosine ring, almost exclusively in the context of CpG dinucleotides.  Low levels of 
DNA methylation in the promoter region is often correlated with active gene 
expression. Approximately 50% of genes are associated with CpG islands in their 
promoter region and these are usually hypo-methylated and hence, capable of 
transcriptional activation (Figure 17). By contrast, methylation near the 
transcriptional start site often inhibits gene expression which occurs through the 
recruitment of transcriptional repressor proteins such as methyl binding proteins 
(MBDs) and histone deacetylases (HDACs) (Fujita et al., 1999).  
             DNA methylation differentially regulates gene expression in a tissue-specific 
and developmental-stage-specific manner. The methylation pattern is established 
during development and is normally maintained throughout the life of an individual. 
However, during older age this pattern can become less stringent, leading to an 
increase in genomic instability (Yoo and Jones, 2006).  
             DNA methylation is important in the initiation and progression of cancer and 
this relationship has been extensively studied. Interestingly, promoter 
hypermethylation but genome wide hypomethylation have been observed in cancer 
leading to transcriptional inactivation of genes and genomic instability respectively. 
Furthermore, global DNA hypomethylation is linked with the chromatin remodeling 
and nuclear disorganization in cancer cells causing chromosomal instability 
(Hoffmann and Schulz, 2005). In terms of epigenetic cancer therapy, targeting the 
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 DNMTs has been found to be the most effective way to inhibit DNA methylation and 
restore the normal methylation pattern. However, targeting DNMTs is not a specific 
approach and can lead to a genome wide hypomethylation and activation of certain 
deleterious oncogenes.  
 
                         DNA methylation patterns 
A) Normal cells 
Exon2 Exon1 
 
 
Figure 17. Schematic representation of DNA methylation: A) In normal cells, the 
CpG islands in the 5' regions of many genes are unmethylated and ready to be expressed 
B) In cancer cells, CpG islands in the 5' regions of many tumor-suppressor genes are 
methylated, and silenced. This is considered as one of the major mechanisms of tumor-
suppressor gene inactivation. 
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 Histone modifications: 
             Eukaryotic DNA is intimately associated with a family of small basic histone 
proteins, to form a highly ordered and condensed protein: DNA complex called 
‘chromatin’. In other words, chromatin is the physiological template of eukaryotic 
genetic information. The fundamental unit of the chromatin is called ‘nucleosome’ 
(Figure 18), which consists of approximately 147 base pairs of DNA wrapped around 
an octamer of histone core proteins. This octamer is composed of two copies of each 
H2A, H2B, H3 and H4 or sometimes natural variants of histone proteins (Hake et al., 
2004). Generally, two different forms of chromatin have been described: 
‘heterochromatin’ a tightly compacted form which leads to transcriptional repression 
and ‘euchromatin’ a more open conformation which leads to transcriptional activation 
(Wolffe and Kurumizaka, 1998). 
 
 
Figure 1
called as
octamer 
              Nucleosome - basic unit of chromatin 
8. Structure of nucleosome: Fundamental unit of chromatin is 
 a ‘nucleosome’ that consists of 147 bp DNA wrapped around an 
of two copies of each histone H2A, H2B, H3 and H4 
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               Remodeling of chromatin can be achieved by several different but 
interconnected mechanisms 1) covalent modifications of histones 2) exchange of 
‘generic’ core histones with histone variants 3) disruption of the basic nucleosome 
structure and histone DNA contacts and 4) modification of DNA itself (Hake et al., 
2004). Among these, covalent modifications of histones have been extensively 
investigated. Histone tail domains are subject to a diverse array of covalent 
modifications that include: acetylation, methylation, phosphorylation, ADP-
ribosylation, ubiquitination, sumoylation, glycosylation, biotinylation and 
carbonylation.  
             Histone acetylation is most probably the best-studied modification and occurs 
on the lysine residues of tail domains of histones mainly histone H3 and H4. The 
overall level of acetylation of core histones results from the steady-state balance 
between the opposing activities of two groups of histone modifying enzymes: histone 
acetyl transferases (HATs) which cause acetylation while histone deacetylases 
(HDACs) which are responsible for deacetylation. HATs and HDACs are super- 
families of enzymes which are summarized in (Table 6 and 7). 
             In general, an increased level of histone acetylation (hyperacetylation) is 
associated with the euchromatin state (open chromatin), while lower level of histone 
acetylation (hypoacetylation) is often found in heterochromatin state (closed 
chromatin) (Fischle et al., 2003b; Strahl and Allis, 2000; Turner, 2000). HATs add an 
acetyl group (negative charge) on the lysine residues of histone tails, loosening the 
contacts between histones and a negatively charged DNA (open chromatin). On the 
other hand, removal of acetyl group leads to a tighter association between histones 
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 and DNA (closed chromatin). Thus, histone acetylation plays significant role in 
transcriptional regulation of multiple genes by altering chromatin structure. Histone 
hyperacetylation leads to transcriptional activation by opening chromatin structure 
whereas histone hypoacetylation leads to transcriptional repression by closing 
chromatin structure (Figure 19). Histone deacetylase inhibitors (HDACi) inhibit the 
deacetylases and they are summarized in (Table 8). HDACi are commonly used to 
study histone acetylation as they can induce histone hyperacetylation and activate 
transcription of various genes. Above all, several of HDACi are currently in different 
phases of clinical trials which can prove as effective anticancer agents in future.      
Chromatin & histone acetylation 
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Figure 19. Histone acetylation and chromatin alterations: Histone acetylation is a 
dynamic modification. Histone acetylation (euchromatin) is caused by histone acetyl 
transferases (HATs) while deacetylation (heterochromatin) is caused by histone deacetylases 
(HDACs). HDACi can lead to hyperacetylation and in turn transcriptional activation of 
certain genes  
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 Table 6. Known histone acetyltransferases (HATs) 
 
 
HAT Organism Transcriptional/ other 
function 
Histone specificity 
GNAT family 
Gcn5 
GCN5 
PCAF 
Hat1 
Elp3 
Hpa2 
 
MYST family 
Esa1 
Sas2 
Sas3 
Tip60 
HBOI 
MORF 
MOZ 
MOF 
 
p300/CBP 
 
Others 
SRC-1 
ACTR 
TIF2 
TAFII250 
TFIIIC 
 
Yeast 
Human 
Human 
Yeast 
Yeast 
Yeast 
 
 
Yeast 
Yeast 
Yeast 
Human 
Human 
Human 
Human 
Human 
 
Human 
 
 
Human 
Human 
Human 
Yeast/Human 
Human 
 
Coactivator 
Coactivator 
Coactivator 
Histone deposition 
Transcript elongation 
- 
  
 
Cell cycle progression 
Silencing 
Silencing 
Coactivator 
Coactivator 
Coactivator 
Coactivator 
Dosage compensation 
 
Global Coactivator 
 
 
Coactivator 
Coactivator 
Coactivator 
RNA Pol-II transcription 
Coactivator 
 
 
 
H3/H4 
H3/H4 
H3/H4 
H4 
- 
H3/H4 
 
 
H4/H3/H2A 
- 
H3/H4/H2A 
H4/H3/H2A 
- 
H3/H4/H2A 
- 
H4/H3/H2A 
 
H2A/H2B/H3/H4 
 
 
H3/H4 
H3/H4 
- 
H3/H4 
H2A/H3/H4 
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 Table 7. Known histone deacetylases (HDACs) 
 
 
Class/HDACs Organism Transcriptional / other 
function 
Complexes 
Class I 
Hos1 
Hos2 
Rpd3 
HDAC1 
HDAC2 
HDAC3 
HDAC8 
 
Class II 
Hda1 
Hos3 
HDAC4 
HDAC5 
HDAC6 
HDAC7 
HDAC9 
HDAC10 
 
 
Class III 
Hst1-4 
Sir2 
SIRT1 
SIRT2 
SIRT3 
SIRT4 
SIRT5 
SIRT6 
SIRT7 
 
Class IV 
HDACII 
 
 
 
Yeast 
Yeast 
Yeast 
Human 
Human 
Human 
Human 
 
 
Yeast 
Yeast 
Human 
Human 
Human 
Human 
Human 
Human 
 
 
 
Yeast 
Yeast 
Human 
Human 
Human 
Human 
Human 
Human 
Human 
 
 
Human 
 
 
Repressor / activator 
Repressor 
Repressor/ activator 
Repressor 
Repressor 
Repressor 
Repressor 
  
 
Repressor 
Repressor 
Repressor 
Repressor 
Repressor/ cell motility 
Repressor/ activator 
Repressor 
Repressor 
 
 
 
Silencing 
Silencing 
Repressor 
Mitotic exit 
Metabolic regulation 
 
 
DNA repair 
Pol-I transcriptional 
activator 
 
- 
 
- 
Set3C 
Rpd3S,L 
   mSin3-HDAC, NuRD,  
Co-REST, N-CoR-2 
N-CoR-1 
 
 
 
Hda1-associated complex 
Homo dimmer 
 
 
 
 
 
 
 
 
 
Set3C 
Sir4, RENT 
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 Table 8. Known histone deacetylases inhibitors (HDACi) 
 
 
Class HDACi In vitro 
IC50 range 
Clinical trial 
Hydroxamic acids 
 
 
 
 
 
 
Short-chain fatty 
acids 
 
 
 
Cyclic tetrapetides 
/ epoxides 
 
 
 
 
 
Benzamides 
 
 
 
Trichostatin A (TSA) 
Suberoyl anilide 
bihydroxamide (SAHA) 
CBHA 
Pyroxamide 
Oxamflatin 
 
Butyrate 
Phenylbutyrate 
Valproic acid 
 
 
Trapoxin 
HC-toxin 
Chlamydocin 
Depudesin 
Apicidine 
Depsipeptide (FK228) 
 
N-acetyldinaline (CI-994) 
MS-275 
nM 
µM 
 
µM 
µM 
nM 
 
mM 
mM 
mM 
 
 
nM 
nM 
nM 
µM 
nM- µM 
nM 
 
µM 
µM 
 
 
Phase II 
 
 
 
 
 
 
Phase I 
Phase I & II 
 
 
 
 
 
 
 
Phase II 
 
 
Phase I 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 53
              Histone methylation has been of a great interest in the last few years in 
chromatin biology. In contrast to histone acetylation which can occur only on lysine 
residues, methylation of histones can occur on both lysine and arginine residues. In 
addition, lysines can be mono-, di-, or tri-methylated whereas arginines can be mono- 
or di-methylated (symmetrically or asymmetrically), thus adding another layer of 
complexity to this modification dependent gene regulation (Hake et al., 2004). Lysine 
methylation is carried by a group of enzymes called as lysine methyltransferases 
which have enormous specificity. Histone methyl transferases (HMTs) are 
characterized by a conserved SET domain. The SET domain proteins are divided into 
subgroups (depending upon homology within the SET domain) as SUV3, SET1, 
SET2 and RIZ (Yoo and Jones, 2006). Lysine methylation was considered to be a 
stable or permanent modification for many years until the discovery of first 
demethylase, LSD1 (Shi et al., 2004). This study was one of the major breakthroughs 
in the field of histone methylation and provided the first piece of evidence that 
histone methylation is a dynamic process. As opposed to histone acetylation which 
often leads to gene activation, histone methylation can cause either gene activation or 
repression depending upon the lysine residue which gets methylated. Three 
methylation sites are so far implicated in transcriptional activation: H3K4, H3K36 
and H3K79 and in repression: H3K9, H3K27 and H4K20 (Kouzarides, 2007).  
            There are two types of demethylase domains, with distinct catalytic reactions: 
the LSD domain and JmjC domain. As per Shi’s initial observations, LSD1 can 
specifically demethylate H3K4 and repress transcription (Shi et al., 2004). 
Interestingly Metzger et al demonstrated that LSD1 can associate with androgen 
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 receptor (AR), and demethylate H3K9 leading to transcriptional activation of AR-
target genes (Metzger et al., 2005). Furthermore, JMJD2A, JMJD2B, JMJD2C and 
JMJD2D have been reported to demethylate H3K9 (Cloos et al., 2006; Fodor et al., 
2006; Shin and Janknecht, 2007; Tsukada et al., 2006). Since 2004, discovery of  the 
first histone demethylase LSD1, a total 7 histone demethylases have been 
documented. The precise functional significance of all of these enzymes is still not 
clear. Similarly, arginine methylation can also cause activation or repression of 
transcription and the enzymes responsible (protein arginine methyltransferase, 
PRMT) are recruited to the promoters by transcription factors (Lee et al., 2005).  
             Phosphorylation is another important and well understood histone 
modification.  Histone phosphorylation is often associated with chromosome 
condensation that includes mitosis, meiosis, apoptosis and DNA damage. One of the 
earliest recognized responses to DNA damage is the phosphorylation of the histone 
variant γ-H2AX in mammalian cells (Fillingham et al., 2006). During DNA 
replication, condensation and decondensation of chromatin are two important 
processes. The phosphorylation at H3S10 by aurora B kinase and the phosphorylation 
at H3T3 by Has-pin kinase play significant roles during mitosis (Kouzarides, 2007). 
Little is known about histone phosphorylation and gene expression, however, a role 
for H3S10 has been demonstrated for activation of NFKB-regulated genes and 
immediate early genes such as c-fos and c-jun. Recently, global ChIP on CHIP 
analysis of many kinases in budding yeast has shown that they are present on the 
chromatin of specific genes and this might have implications in signal transduction 
(Pokholok et al., 2006). 
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 Histone code hypothesis: 
             Strahl and Allis (2000) proposed the ‘histone code’ hypothesis to explain the 
complex nature of differential patterns of histone modification readouts (Strahl and 
Allis et al., 2000). According to this hypothesis, one histone modification or specific 
combinations of histone modifications can affect distinct downstream events either by 
altering chromatin structure and or by generating a binding platform for protein 
effectors molecules which can specifically recognize the modifications and initiate 
gene transcription or repression (Fischle et al., 2003a; Strahl and Allis, 2000). In one 
of the very first examples demonstrating the cooperativity of histone modifications in 
the regulation of gene expression, phosphorylation of H3-S10 together with H3-K14 
acetylation was shown to prevent the methylation of H3-K9.  
             Histone modifications either promote or prevent the binding of proteins and 
protein complexes that drive particular regions of the genome into active transcription 
or repression. Proteins containing bromodomains and chromodomains have been 
shown to have affinity for acetylated and methylated lysine residues respectively 
(Figure 20). The histone code hypothesis states that the modification would recruit 
proteins or protein complexes which in turn would cause chromatin to take as a 
certain conformation and spread the pattern to the neighboring region. 
Heterochromatin protein-1 (HP1) associated heterochromatin formation is one of the 
best examples of this phenomenon. The chromodomain of HP1 interacts with a 
trimethylated H3-K9 and recruits SUV39H1 which is a histone H3-K9 methylase that 
subsequently methylates the H3 tail of the adjacent nucleosome at lysine 9 to mediate 
HP1 binding and further spreading of heterochromatic regions (Lachner et al., 2001). 
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Translation of histone code 
Kinase HAT HMT
 
 
Figure 20. Translation of histone code: Protein modules of histone modifying enzymes  
that have been shown to interact with site-specific methylation (chromodomain), 
acetylation (bromodomain) and phosphorylation (domain in 14-3-3 proteins) marks in 
histone amino-tails. Ultimately, these modifications can act alone or in combination to 
alter chromatin structure and initiate specific gene transcription or repression.   
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 HYPOTHESIS AND RATIONALE 
 
Gaps in the knowledge: 
             The molecular events that occur during the initiation of prostate cancer 
remain enigmatic. However, it is clear that a first genetic hit (haploid loss of Nkx3.1) 
during tumor development confers a selective growth advantage to the affected cells, 
creating a reservoir of cells that are more susceptible for subsequent mutations. 
Magee and colleagues (Magee et al., 2003) performed gene expression profiling on 
the prostates of Nkx3.1-mutant mice and identified a class of genes that shows 
exquisite dosage sensitivity i.e. the expression of these genes in Nkx3.1+/- cells was 
similar to that in Nkx3.1-/- cells (Magee et al., 2003). In addition, this study suggested 
that Nkx3.1 dosage might regulate target gene activation in a stochastic manner. 
These observations are consistent with a model of haploinsufficient tumor 
suppression (Figure 13) in which reduction in Nkx3.1 dosage increases the 
probability of inactivation of select target genes important for tumorigenesis 
(Abdulkadir, 2005; Magee et al., 2003). Nevertheless, at the molecular level, the 
mechanisms involved in haploinsufficient tumor suppression and dosage-sensitive, 
stochastic gene regulation by Nkx3.1 have remained unclear. In addition, none of 
these dosage-sensitive target genes have been shown to functionally affect prostate 
cell growth or tumorigenicity. As my dissertation work, we have explored the 
molecular mechanism of haploinsufficient tumor suppression by Nkx3.1 and 
examined the dosage-sensitive and stochastic Nkx3.1 target gene regulation in 
prostate. Furthermore, we have functionally characterized one of the dosage-sensitive 
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 targets, intelectin / omentin and demonstrated its role in suppressing prostate cell 
growth and tumorigenicity. 
 
Hypothesis: 
             We hypothesize that dosage-sensitive, stochastic target gene regulation by 
Nkx3.1 is one of the mechanisms of haploinsufficiency in prostate tumor initiation 
and that phenomenon can be mediated by alterations in the active (on) versus inactive 
(off) states of chromatin. 
 
Rationale behind hypothesis: 
             Previous studies in transgenic mice and Drosophila support that the dosage of 
transcription factors and stochastic on and off gene expression is related to changes in 
higher order chromatin (Ahmad and Henikoff, 2001; Lundgren et al., 2000). 
Lundgren and colleagues investigated the mechanisms of transcriptional activation in 
heterochromatin by utilizing FISH technique to directly visualize changes in 
chromatin organization during activation of the heterochromatic λ5 transgene in mice 
(Lundgren et al., 2000). They observed that activation of transcription was stochastic 
and dependent on the dosage of activating transcription factor early B cell factor 
(EBF). Further, reduction in dosage of EBF resulted in a reduced frequency of 
localization of the transgene to the outside of the heterochromatin complex and lower 
levels of transcription. These observations provided evidence that transcription factor 
dosage can initiate changes in higher order chromatin during the initial stages of gene 
expression (Lundgren et al., 2000). 
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              Ahmad and Henikoff examined the behavior of a GFP reporter subject to 
position-effect variegation (PEV) in Drosophila. In their studies, the reporter gene 
displayed an expression pattern suggestive of repeated rounds of stochastic activation 
and inactivation of gene expression, resulting in patches of cells (mosaic pattern) 
expressing the reporter (Ahmad and Henikoff, 2001). In addition, their study 
established a correlation between fluctuations of chromatin states with the stochastic 
activation or inactivation of gene expression. Firstly, their results revealed that the 
fluctuations in the chromatin state of reporter genes can uncover transcription factor 
binding sites. Secondly, they observed that the recruitment of chromatin modulating 
activities after transcription factor binding can reduce the rate of heterochromatin 
reformation (Ahmad and Henikoff, 2001).  
             More recent studies in budding yeast indicate a role for chromatin remodeling 
and interconversion between inactive to active promoter states in the control of 
stochasticity in gene expression (Raser and O'Shea, 2004). Raser and O’Shea 
employed the two reporter system to measure the noise in gene expression in yeast 
cells. These studies revealed that the intrinsic noise in the transcription results from 
the slow interconversion between inactive to active promoter states due to stochastic 
chromatin remodeling events as shown in Figure 15 (Raser and O'Shea, 2004). 
Furthermore, this study revealed that mutations in the TATA box upstream of the 
repressible acid phosphatase PHO5 do not change the level of noise associated with 
PHO5 expression. However, mutations in genes (SNF6, ARP8, GCN5), which 
encode the components of chromatin remodeling complex increase the level of noise 
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 supporting the role for chromatin remodeling in the control of noise in gene 
expression (Raser and O'Shea, 2004).   
 
Specific aims: 
            We tested our hypothesis in Nkx3.1-mutant mouse prostates with the 
following specific aims: 
Aim I: We first determined the effects and mechanism of alterations in active (open) 
versus inactive (close) chromatin states on the dosage-sensitive, stochastic Nkx3.1 
target gene regulation (Chapter IV). 
Aim II: We established the functional significance of dosage-sensitive Nkx3.1 target 
genes in prostate cancer (Chapter V). 
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 CHAPTER II 
 
MATERIALS AND METHODS 
 
ChIP assays, two-step ChIP assays: 
           ChIP assays were performed using the ChIP assay kit from Upstate 
Biotechnology (Lake Placid, NY) with the following modifications. Anterior 
prostates from Nkx3.1-mutant mice (Abdulkadir et al., 2002) were excised, snap-
frozen and ground into a powder under liquid nitrogen. The tissue was fixed in 1% 
formaldehyde/PBS supplemented with the Complete protease inhibitor cocktail 
(Roche Diagnostics, Basel, Switzerland), 1 mM Na VO  and 1 3 4 µg ml  pepstatin for 
15 min at room temperature. Fixation was stopped by the addition of glycine to a final 
concentration of 125 mM. After several washes in ice-cold PBS, the tissue pellet was 
resuspended in NEBA buffer (10 mM HEPES, 10 mM KCl, 0.1 mM EDTA, 0.1 mM 
EGTA) supplemented with Complete protease inhibitor cocktail, 1 mM Na VO  and 
1 
-1
3 4
µg ml  pepstatin, dounce homogenized and incubated for 15 min on ice. NP40 
(0.5%) was added and samples were vortexed for 30 s before collecting the nuclei. 
Subsequently, the nuclear fraction was lysed in nuclear lysis buffer (50 mM Tris-HCl 
pH 8.1, 10 mM EDTA, 1% SDS, Complete protease inhibitor cocktail, 1 mM 
vanadate and 1 
-1
µg ml  pepstatin). Chromatin was sheared to a size of approximately 
500-700 base pairs (Figure 21) and diluted 1:10 with ChIP dilution buffer. Samples 
were pre-cleared and precipitated overnight at 4 °C with the following antibodies: 
pan-acetylated H3 (Upstate, 06-599), pan-acetylated H4 (Upstate, 06-598), Nkx3.1 
-1
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 (Santa Cruz, T-19X), PCAF (Santa Cruz, H-369X) and rabbit or mouse IgG (Santa 
Cruz). Immune complexes were collected with salmon-sperm DNA−saturated 
protein-A/G Sepharose for 3 h and washed extensively following the manufacturer's 
protocol. Samples were reverse cross-linked at 65 °C overnight with 0.3 M NaCl and 
30 µg RNAse. Input and bound DNA was extracted with PCR purification kit 
(Qiagen) and analyzed by quantitative PCR (Applied Biosystems 7300) using SYBR-
Green. ChIP values are presented as fold enrichment and calculated as [IP Ab/ Input 
Ab] / [IP IgG/ Input IgG] as described earlier (Magee et al., 2006; Polo et al., 2007).  
           Two-step ChIP assays were performed as described earlier (Kim et al., 2005). 
In brief, components were eluted from the first immunoprecipitation reaction by 
incubation with 10 mM dithiothreitol (DTT) at 37 °C for 30 min and diluted 1:50 in 
ChIP dilution buffer followed by reimmunoprecipitation with the second antibodies. 
Two-step ChIP was performed in essentially the same way as the first 
immunoprecipitations. 
Optimization for ChIP sonication conditions  
12sec*12pulses*setting10 
1000 bp 
500 bp 
 
Figure 21. Optimization of sonication conditions for ChIP assays: Note the optimal 
chromatin shearing (500-700 bp) by Fisher scientific sonicator (12s*12 pulses*setting 10) 
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 Trichostatin A Preparation: 
           Trichostatin A was obtained (Sigma biochemical) and dissolved into ethanol. 
Several aliquots of stock solutions of 500 µg/ml, 200 µg/ml and 100 µg/ml were 
prepared and stored at -200C. Fresh aliquots were used for separate experiments. 
 
Mouse prostate explants and TSA treatment: 
            Mouse prostate explants were performed as described previously (Mogal et 
al., 2006). Briefly, anterior prostates were excised, minced and treated with either 
vehicle (ethanol), Trichostatin A (Sigma) at a concentration of 500 ng/ml for 8 h or 5-
azacytidine 1 µM for 24 h. Prostate tissue was harvested in a complete DMEM/F12 
50/50 media.  RNA was extracted with Trizol reagent, cDNA was synthesized and 
analyzed by quantitative RT-PCR (Applied Biosystems 7300) using the SYBR-Green 
method as described (Mogal and Abdulkadir, 2006). The explant experiments were 
independently repeated under the same conditions.  
            To our knowledge, conditions for TSA treatment of mouse prostate explants 
have not been determined. We therefore, first determined the effects of TSA 
treatment on histone acetylation in mouse prostate tissue explants using different 
concentrations of TSA (250 ng/ml, 500 ng/ml and 1000 ng/ml) and at different time 
points (8 hr, 16 hr and 24 hr) and found 500 ng/ml TSA for 8 hrs to be the optimal 
condition for inducing histone H3 acetylation (Figure 22).  
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 TSA ng/ml*8 hr Vehicle 
-        250      500      1000 
Optimization of TSA treatment 
Ac-H3 
Total histone H3 
 
 
Figure 22. Optimization of TSA treatment for prostate explants: Mouse prostates 
were treated with either vehicle or TSA (250 ng/ml, 500 ng/ml and 1000 ng/ml for 8h) and 
efficiency of TSA treatment was confirmed by western blot analysis for acetylated histone 
H3. Note that maximum acetylation was achieved at 500 ng/ml concentration of TSA.   
  
 
 
RNA isolation and Quantitative RT-PCR Analysis: 
            RNA was extracted with Trizol reagent (Invitrogen) after 8 and 24 h 
treatments from mouse prostate tissue and human prostate and breast cancer cells 
respectively. Samples were dissolved in RNase-free water and quantified by 
spectrophotometric readings at 260 nm (A260). Purity of total RNA was determined by 
the A260/A280 and A260/A230 ratio, and then integrity of RNA samples was confirmed by 
electrophoresis on 1% agarose gels. 1 µg of total RNA was reverse transcribed using 
primer cocktail (200 ng/µl oligodT and 50 ng/µl of random hexamer). Reaction mix 
contained 10 mM dNTP's, 0.1 M DTT, RNAsin and M-MLV reverse transcriptase 
(Gibco/BRL 200 units/µl). Reaction conditions were 68 °C for 10 min and 42 °C for 
60 min. RNase free water was used to make final volume of 250 µl. cDNA samples 
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 were then boiled for 5 min and stored at −20 0C. PCR was performed by SYBR® 
green PCR Master Mix (Applied Biosystems).The increase in fluorescence of the 
SYBR green dye was monitored using a GeneAmp 5700 sequence detection system 
(Applied Biosystems). All of the PCR reactions were performed in triplicate and 
independently repeated at least two to three times. 
Western Blot Analysis: 
 
             Mouse prostate explants were treated with TSA as described above and 
lysates were prepared using extraction buffer (50 mM Tris-HCl-buffered saline, pH 
7.4, 1% Triton X-100, 1% Nonidet P-40, 5 mM CaCl2, 2 mM phenylmethylsulfonyl 
fluoride, and 3 mM hydrogen peroxide). Nuclear protein was extracted by the method 
of Dignam et al (Dignam et al., 1983). Protein concentrations were measured using 
the Bio-Rad DC protein assay reagent. Extracts containing 20–30 µg of protein were 
electrophoresed on a 12% SDS-polyacrylamide gel and blotted onto an ImmobilonTM 
membrane (Millipore). The blotted membrane was blocked with 5% fat-free dry milk 
for 1 h at room temperature and incubated with the rabbit polyclonal acetylated 
histone 3 antibody (1:1000, Upstate) at 4°C overnight. The membrane was then 
incubated for 1 h at room temperature with a peroxidase-labeled goat anti-rabbit 
antibody (1:3000, Bio-Rad). The membrane was rinsed, treated with ECL reagent 
(PerkinElmer Life Sciences) for 1 min and exposed to x-ray film at room temperature 
for 30 sec to 1 min. Membranes were stripped and then incubated with rabbit 
polyclonal total histone 3 antibody (1:1000, Upstate) and Nkx3.1 antibodies (Santa 
Cruz T19). To confirm knockdown efficiency for stable LNCaP cell lines, lysates 
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 from LNCaP cells were prepared and probed with Nkx3.1, intelectin (Phoenix 
pharmaceuticals Inc) and actin (Santa Cruz) antibodies.  
 
Immunohistochemistry assays: 
           Immunohistochemistry for paraffin-embedded section was performed as 
described (Abdulkadir et al., 2001). In brief, paraffin-embedded sections (6 µm thick) 
were deparaffinized, rehydrated, and subjected to antigen retrieval in 10 mmol/L 
citrate buffer, pH 6.0. The following antibodies were used: acetylated H3 (1:100) and 
acetylated H4 (1:100) antibodies. Immunoreactivity was detected using 3,3‘-
diaminobenzidine substrate, and slides were counterstained with hematoxylin before 
they were mounted and viewed. 
 
Co-immunoprecipitation: 
 
           For immunoprecipitation experiments, LNCaP cells were grown in RPMI 1640 
supplemented with 5% FBS at 370C with 5% CO2.  The cells were lysed in 0.5 ml of 
extraction buffer. The lysates were incubated on ice for 30 min and subsequently 
cleared by centrifugation at 12,000 rpm for 15 min at 4 °C. The protein concentration 
of the lysates was determined by Bio-Rad DC protein assay reagent. 50 µl of protein 
A/G Plus-agarose beads (Santa Cruz) were added to 1.5-ml microtubes containing 
500 µl of cellular lysate (500 µg protein) and rotated at 4 °C for 1 h. The samples 
were centrifuged for 1 min at 2000 rpm. The samples were incubated with primary 
antibodies [2 µg each of rabbit IgG, goat IgG, Nkx3.1 or PCAF antibodies (Santa 
Cruz)] and the mixture was rotated overnight at 4 °C.  Immune-complexes were 
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 collected with 50 µl of protein A/G Plus-agarose beads for 2 hr at 4 °C. The beads 
were pelleted by gentle centrifugation and washed five times with 1 ml of ice-cold 
extraction buffer. After the final wash, the precipitated protein complexes were 
resuspended in SDS sample loading buffer and boiled for 5 min. The samples were 
vortexed, centrifuged and the supernatants were analyzed by Western blotting. 
 
RNA Interference: 
            Lentiviral NKX3.1 shRNA construct (RHS4186) and retroviral intelectin 
shRNA construct (RHS1764) were purchased from Open Biosystems. Intelectin 
shRNA was cloned into the same lentiviral vector for a valid comparison with 
shNKX3.1. The constructs were transfected into LNCaP cells with superfect reagent 
(Qiagen). Stable clones were selected in a complete medium supplemented with 500 
µg/ml of G418 for two weeks. The NKX3.1 and intelectin protein knockdown 
efficiencies were confirmed by western blotting.  
 
Cell growth analysis: 
             For cell growth analysis, 1 × 105 cells were seeded in 10 cm plates in 
duplicates supplemented with a complete RPMI medium. Two different Nkx3.1 and 
intelectin knockdown cell clones were used. Cells were counted at different time 
points: day 1, day 3, day 6 and day 8. At least two independent experiments were 
performed.  
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 MTT assays: 
            The antiproliferative effects of intelectin were determined by MTT (ATCC) 
proliferation assays. Briefly, DU145 cells or shNKX3.1 LNCaP cells were seeded at a 
density of 103 cells in quadruplicate in a 96-well flat-bottomed tissue culture plate in 
100 µl of complete medium. Intelectin (generous gift from Dr. Gong (Yang et al., 
2006)) or control vectors (stratagene) were transiently transfected for 24 h and the 
transfection efficiency was confirmed by western blot analysis. At variable indicated 
times 10 µL of 3-[4,5-dimethylthiazolyl-2]-2,5-diphenyl-tetrazolium bromide (MTT 
reagent) was added to each well and incubated for 2-4 h at 37°C until purple 
precipitates were visible. The reaction was terminated by addition of 100 µL of 
detergent reagent (ATCC) in the dark for 2 h and the absorbance was recorded at 570 
nm. At least two independent experiments were performed. Results are presented as 
Mean ± SD. 
 
Soft agar colony formation assays: 
             For soft agar colony formation assay, 0.8 × 105 cells were suspended in a 
complete RPMI medium containing 0.3% of agarose and overlaid onto a bottom layer 
of solidified 0.5% agar in a complete RPMI medium. The colonies were allowed to 
grow for 2 weeks. The colonies (greater than 0.5 mm size) were counted under light 
microscope. At least two independent experiments were performed. 
 
 
 
 69
 In Vivo Xenograft studies: 
           Approximately, 2 × 106 cells suspended in Matrigel (BD Biosciences) at 50:50 
volumes for a total volume of 400 µl/ injection site were injected subcutaneously in 
right and left flanks of male nude mice ( 8 weeks old, Jackson Lab). All the mice 
were monitored daily and once the tumor xenograft started growing, the tumor sizes 
were measured twice weekly in two dimensions (Width and Length) with calipers. 
Average tumor volume was calculated for each tumor site by formula V = 0.5 × L × 
W2. At the termination of the experiment, mice were sacrificed; tumors were excised 
and weighed to record mean tumor mass. All animal protocols are followed as per 
approved institutional guidelines of Vanderbilt University. 
 
Statistical analysis: 
            Data were analyzed by t-test and results were considered significant at P ≤ 
0.05. Results are presented as Mean ± SD.  
 
Mathematical Model: 
            In collaboration with Dr. Philip Crooke from the Department of Mathematics, 
Vanderbilt University, we developed a mathematical model based on our previous 
and current observations. We primarily developed a model for two reasons; firstly to 
recapitulate our experimental findings and secondly, to make some predictions that 
can be tested experimentally in future. 
             Let Ga(t) denote the level of active genes at time t, Gin(t) the level of inactive 
genes, Nkx(t) the level of Nkx3.1, HAT(t) the level of histone acetyltransferase, 
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 NkxHAT(t) the level of the Nkx3.1-HAT complex and mRNA(t) the level of target 
gene mRNA (either intelectin or probasin). The mRNA pathway is characterized by 
three constants: K1, K2 and K3. We assume that the total number of genes, G0, is 
conserved so that Ga(t)+Gin(t)  = G0 . Using compartment analysis, we can write down 
individual differential equations for a compartment, e.g. the active gene compartment. 
Individual components in the pathway do not necessarily mean creation or 
consumption of the substance in the compartment. For example, mRNA dynamics are 
governed by Ga(t) and Nkx(t), but these components are not consumed in the creation 
of mRNA(t). Using the above scheme and the diagram in Fig. 33A, we construct a 
system of ordinary differential equations: 
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Notice that if we add the second and third differential equations, we find: 
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This permits us to replace Gin(t) by G0 _ Ga(t). Using this expression in the differential 
equation for Ga(t), we find 
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 Hence, the model simplifies to the coupled system: 
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where λ  is a constant that determines the rate of formation of the Nkx3.1-HAT 
complex, HAT(t) is a prescribed function and Nkx(t) an experimentally determined 
function (Magee et al., 2003), assuming that Nkx3.1 mRNA levels reflect protein 
levels. The outcome variable for the model is mRNA(t). This can be computed by 
integrating the differential equation for mRNA(t). In particular,  
.)()(3)0()(
0
∫ ⋅+= t a dGNkxKmRNAtmRNA τττ                                                                  
(9) 
We will take mRNA(0) = 0. The mRNA(t) represents target gene levels (intelectin or 
probasin). The dynamics of the model are dependent on the ratio of initial 
conditions,
)0(
)0(
Gin
Ga , which reflects target gene chromatin accessibility and introduces 
a stochastic component into the model, and the functions Nkx(t) and HAT(t). For the 
simulations in this paper, we have assumed that 
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For modeling the effects of TSA, the kinetic parameter and the chromatin 
accessibility represented by the initial active/inactive gene ratio 
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 assumed to depend on the TSA level, which we assume is constant over the course of 
the experiment. Our mathematical formulation for the effect of TSA (suitably 
normalized to be dimensionless) on K2 is given by the relationship: 
.
RK
R1(R) and 
TSAK
TSA(TSA) constant, a is  where
 (10)                                                                                            ))()(1(2 0
+−=+=
−=
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In the simulations, we have assumed that TSA and R0 are fixed in time. The constants 
Kµ and Kσ  were chosen to fit the experimental data. In our model, the rate constants 
for intelectin and probasin were kept the same, although in theory they could be 
different. Remarkably, differentiating between probasin and intelectin by the initial 
active/inactive gene ratio (i.e. chromatin accessibility) alone, keeping all other 
parameters constant, was sufficient to simulate experimental findings. All simulations 
were performed with Mathematica (Wolfram Research, Inc., Champaign, IL).  
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 CHAPTER III 
DETERMINATION OF SUITABLE HOUSEKEEPING GENE FOR QRT-PCR 
ANALYSIS FOLLOWING TRICHOSTATIN A TREATMENT 
 
Introduction: 
             Assessment of gene expression by RT-PCR is based on comparison with 
internal standards, so called housekeeping genes. The use of such genes as internal 
control relies on the fact that ideally they should exhibit a constant basal level of 
expression which is consistent, non-regulated and independent of the cell cycle 
(Selvey et al., 2001). 18S ribosomal RNA (rRNA), glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) messenger RNA (mRNA) and β actin mRNA are 
commonly used as such internal standards. However, it has now become clear that the 
expression of these genes can be affected by various factors like developmental and 
differentiation status, cell-cycle phase, pathological conditions and drug treatments 
(Matyas et al., 1999; Wu and Rees, 2000; Yamada et al., 1997). GAPDH is a 
glycolytic enzyme, encoded by a single gene and it has the advantage of being highly 
conserved in different species (Bhatia et al., 1994; Fort et al., 1985). β actin mRNA 
and 18S rRNA are constitutively expressed in eukaryotic cells and their expression is 
thought to remain constant even during cell growth and during different phases of the 
cell cycle (Edwards and Denhardt, 1985). However, some studies have indicated 
increased expression of GAPDH and β actin mRNAs in carcinomas, in regenerating 
tissues after resection and during postnatal development (Calvo et al., 1991; Cohen et 
al., 1991). Therefore, 18S rRNA is widely used as a housekeeping gene. However, no 
one single housekeeping gene is perfect under all experimental conditions and 
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 therefore, it is necessary to characterize the suitability of various housekeeping genes 
to serve as internal controls under particular experimental conditions (Zhong and 
Simons, 1999).  
            An emerging area of research in cancer involves the study of epigenetic 
aberrations and their contribution to malignant transformation and progression of 
cancer. DNA methylation and histone modifications (such as acetylation, 
methylation, phosphorylation and ubiquitination) by specific chromatin-modifying 
enzymes play essential roles in both tumor initiation and progression (Li et al., 2005). 
Among all of these histone modifications acetylation is arguably the best-studied 
modification. The actual levels of acetylation of the core histones result from steady 
state balance between the opposing activities of histone acetyl-transferases (HATs) 
and histone deacetylases (HDACs) (Hake et al., 2004). Over the years many different 
types of HDAC inhibitors (HDACi) have been developed, ranging from complicated 
structures of bacterial or fungal origin [trichostatin A (TSA), trapoxin] to the very 
simple butyrate. HDACi are capable of inhibiting HDACs with varying efficiencies 
(at nanomolar to millimolar concentrations) leading to hyperacetylation of histones 
followed by transcriptional activation of certain genes (de Ruijter et al., 2003). TSA 
(at nanomolar concentrations) is the most commonly used HDACi. Furthermore, 
modulation of histone acetylation is currently being explored as a therapeutic strategy 
in treatment of cancer. Specifically, inhibition of histone deacetylases by trichostatin 
A (TSA) has been shown to prevent tumorigenesis and metastasis (Ailenberg and 
Silverman, 2002). We have been interested in studying the role of chromatin state and 
histone acetylation on stochastic, dosage-sensitive gene regulation by Nkx3.1 in 
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 prostate cancer. Nkx3.1 is a homeodomain-containing transcription factor and 
candidate tumor suppressor gene whose deletion in mice leads to the formation of 
prostatic intraepithelial neoplasia (PIN) (Abdulkadir et al., 2002). Loss of Nkx3.1 
protein expression is common in human prostate carcinomas and prostatic 
intraepithelial neoplasia (PIN) lesions and correlates with tumor progression. Further, 
in the prostate, tumor initiation is often linked to loss of heterozygosity at the Nkx3.1 
locus and microarray analysis has identified Nkx3.1 target genes, some of which 
show exquisite dosage sensitivity (Magee et al., 2003). The number of Nkx3.1 alleles 
determines the relative probabilities of stochastic activation or inactivation of a given 
target gene (Magee et al., 2003). In order to study the stochastic and dosage-sensitive 
expression of these genes we needed an accurate internal standard following TSA 
treatment. Here we report the use of ribosomal highly basic 23-kDa protein (rb 23-
kDa, RPL13A) as an adequate internal standard following TSA treatment. 
 
Results:  
Effects of TSA on histone acetylation in mouse prostate explants 
            Mouse prostate explants were treated with TSA (500 ng/ml) or vehicle for 8 
hours and tissue extracts were used for western blot analysis. We observed increased 
levels of acetylated histone H3 in TSA treated samples as compared to vehicle 
(ethanol) treated samples (Figure 23). Our western blot findings confirmed that 
trichostatin A (TSA) treatment was effective in our experimental system. 
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Figure 23. Western blot analysis for acetylated and total histone H3 using mouse 
prostate explants: Mouse prostate explants were treated with either a vehicle (ethanol) or 
trichostatin A (TSA) at a concentration of 500 ng/ml for 8 hours. Proteins were extracted, 
electrophoresed and blotted for acetylated H3 and total histone H3 levels. A) Effect of 
trichostatin A (TSA) on the levels of total histone H3 B) Effect of trichostatin A (TSA) on 
the levels of acetylated histone H3. [Mogal et al, 2006, Mole Cell Probes] 
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 RT-PCR quantitation of housekeeping genes following trichostatin A (TSA) 
treatment in mouse prostate tissue and human prostate cancer (LNCaP) cell line 
           In mouse prostate tissue explants, 18S rRNA (P < 0.002) and β actin mRNA (p 
< 0.01) levels were significantly reduced in TSA treated tissue samples as compared 
to the vehicle treated samples (Figure 24). However, RPL13A and GAPDH mRNA 
levels remained unaffected and showed constant expression in both the vehicle as 
well as TSA treated samples.  
           Next to examine the effect of TSA on the expression of housekeeping genes in 
a cell line we used human prostate cancer cell line (LNCaP). In LNCaP cells, at a 
concentration of 100 ng/ml TSA, 18S rRNA (P < 0.002) and β actin mRNA (p < 
0.01) levels were significantly up-regulated in TSA treated samples (Figure 25A). 
RPL13A and GAPDH mRNA levels remained unaffected and showed constant 
expression in both the vehicle as well as TSA treated samples. Further in LNCaP 
cells, at a concentration of 200 ng/ml TSA, GAPDH mRNA levels were most 
significantly reduced (P <0.001) followed by 18S rRNA levels (P <0.01) and β actin 
mRNA levels (Figure 25B). However, RPL13A mRNA levels remained unaffected at 
higher concentrations of TSA treatment as well and showed constant mRNA level 
expression.  
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Figure 24. Quantitative RT-PCR analysis of housekeeping genes following 
trichostatin A (TSA) treatment in mouse prostate tissue: 18S rRNA (P < 0.002) and β 
actin mRNA (P < 0.01) levels were significantly down-regulated in TSA treated tissue 
samples as compared to the vehicle treated samples. However, RPL13A and GAPDH 
mRNA levels remained unaffected. The data here shown represents the average of three 
different experiments performed in triplicate using same conditions. (**P < 0.005, *P < 
0.05) [Mogal et al, 2006, Mole Cell Probes] 
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Figure 25. Quantitative RT-PCR analysis of housekeeping genes following 
trichostatin A (TSA) treatment in human prostate cancer (LNCaP) cell line. A) 
LNCaP (100 ng/ml TSA): 18S rRNA (P < 0.002) and β actin mRNA (P < 0.01) levels 
were significantly up-regulated in TSA treated samples as compared to the vehicle treated 
samples. However, RPL13A and GAPDH mRNA levels remained unaffected. B) LNCaP 
(200 ng/ml TSA): GAPDH mRNA (P < 0.001) and 18S rRNA (P < 0.01) levels were 
significantly down-regulated in TSA treated samples as compared to the vehicle treated 
samples. However, RPL13A and mRNA levels remained unaffected. The data here shown 
represents the average of two different experiments performed in triplicate using same 
conditions. (**P < 0.005, *P < 0.05) [Mogal et al, 2006, Mole Cell Probes] 
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 RT-PCR quantitation of housekeeping genes following trichostatin A (TSA) 
treatment in human breast cancer (T-47D and ZR-75-1) cell lines 
             Further in order to extend our investigation in non-prostate cells we used two 
different human breast cancer cell lines (T-47D and ZR-75-1). In T-47D cells, at a 
concentration of 100 ng/ml TSA, 18S rRNA (P < 0.005), β actin mRNA (p < 0.003) 
and GAPDH mRNA (P < 0.01) levels were significantly reduced in TSA treated 
samples (Figure 26A). RPL13A mRNA levels remained unaffected. Further at a 
concentration of 200 ng/ml TSA, β actin mRNA (p < 0.005) and GAPDH mRNA (P 
< 0.003) levels were significantly reduced, however 18S rRNA and RPL13A mRNA 
levels remained unaffected (Figure 26B). 
             In ZR-75-1 cells, at 100ng/ml TSA, 18S rRNA (P < 0.001), β actin mRNA (p 
< 0.001) and GAPDH mRNA (P < 0.01) levels were significantly up-regulated in 
TSA treated samples, again RPL13A showed constant expression (Figure 26C). 
Similarly, at a concentration of 200 ng/ml TSA, 18S rRNA (P < 0.05), and GAPDH 
mRNA (P < 0.04) levels were significantly altered in TSA treated samples, however 
RPL13A mRNA and β actin mRNA showed constant expression (Figure 26D). 
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Figure 26. Quantitative RT-PCR analysis of housekeeping genes following 
trichostatin A (TSA) treatment in human breast cancer (T-47D and ZR-75-1) cell 
lines. A) T-47D (100 ng/ml TSA): 18S rRNA (P < 0.005), β actin mRNA (p < 0.003) and 
GAPDH mRNA (P < 0.01) levels were significantly reduced in TSA treated samples as 
compared to the vehicle treated samples. However, RPL13A mRNA levels remained 
unaffected.  B) T-47D (200 ng/ml TSA): β actin mRNA (p < 0.005) and GAPDH mRNA 
(P < 0.003) levels were significantly reduced in TSA treated samples as compared to the 
vehicle treated samples. However 18S rRNA and RPL13A mRNA levels remained 
unaffected.  C) ZR-75-1 (100 ng/ml TSA): 18S rRNA (P < 0.002), β actin mRNA (p < 
0.001) and GAPDH mRNA (P < 0.01) levels were significantly up-regulated in TSA 
treated samples, on the other hand RPL13A mRNA remained unaffected and showed 
constant expression. D) ZR-75-1 (200 ng/ml TSA): 18S rRNA (P < 0.05), and GAPDH 
mRNA (P < 0.04) levels were significantly altered in TSA treated samples, however 
RPL13A mRNA and β actin mRNA showed constant expression. The data here shown 
represents the average of two different experiments performed in triplicate using same 
conditions. (**P < 0.005, *P < 0.05) [Mogal et al, 2006, Mole Cell Probes] 
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 Table 9. Quantitative RT-PCR Primer Sequences 
Gene Species Primer Sequences 
18S rRNA Mouse / Human 
 
5'-CGCCGCTAGAGGTGAAATTCT-3' 
5'-CGAACCTCCGACTTTCGTTCT-3' 
 
β actin Mouse 
 
Human 
5'-ACCAGTTCGCCATGGATGAC-3' 
5'-TGCCGGAGCCGTTGTC-3' 
5'-CCAGCTCACCATGGATGATG-3' 
5'-ATGCCGGAGCCGTTGTC-3' 
 
RPL13A Mouse 
 
Human 
5'-GAGGTCGGGTGGAAGTACCA-3' 
5'-TGCATCTTGGCCTTTTCCTT-3' 
5'-CATCGTGGCTAAACAGGTACTG-3' 
5'-GCACGACCTTGAGGGCAGCC-3' 
GAPDH Mouse 
 
Human 
5'-CATGGCCTTCCGTGTTCCTA-3' 
5'-GCGGCACGTCAGATCCA-3' 
5'-CCCATGTTCGTCATGGGTGT-3' 
5'-TGGTCATGAGTCCTTCCACGATA-3' 
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 Discussion and conclusions: 
            The expression of housekeeping genes such as 18S rRNA, β actin mRNA and 
GAPDH mRNA ideally should remain constant under all experimental conditions, in 
all normal as well as pathological states and during cell growth and various phases of 
the cell cycle (Edwards and Denhardt, 1985). However, some reports suggested that 
these genes may either be up-regulated or down-regulated depending on the 
circumstances (Matyas et al., 1999; Wu and Rees, 2000; Yamada et al., 1997). To 
explore whether expression of these housekeeping genes is modulated under the 
effect of the commonly used histone deacetylase inhibitor (HDACi) trichostatin A 
(TSA), we compared the expression level of these housekeeping genes (18S rRNA, β 
actin and GAPDH) along with the novel ribosomal highly basic 23-kDa protein (rb 
23-kDa, RPL13A). We examined the expression pattern of all four housekeeping 
genes in mouse prostate tissue, human prostate cancer (LNCaP) cell line and human 
breast cancer (T-47D and ZR-75-1) cell lines following vehicle (Ethanol) or 
trichostatin A (TSA) treatment. To our knowledge, this is the first report of testing 
housekeeping genes as RNA internal standards under the effect of trichostatin A 
(TSA).  
            Our results showed that the commonly used housekeeping genes such as 18S 
rRNA, β actin mRNA, GAPDH mRNA levels were significantly altered in the TSA 
treated samples as compared to the vehicle treated samples. It is interesting that TSA 
can either up-regulate (e.g. LNCaP and ZR-75-1 at 100 ng/ml TSA) or down-regulate 
(e.g. prostate explants, T-47D, LNCaP and ZR-75-1 at 200 ng/ml TSA) expression of 
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 these genes. This could be due to an ‘optimal dose response effect’ of TSA 
(100 ng/ml Vs 200 ng/ml) in the particular tissue or cell line. Regardless of the 
underlying reason, these findings underscore the importance of testing the suitability 
of housekeeping genes in different experimental systems.  
            The levels of ribosomal RNA, which make up ~ 80% of total RNA, are 
thought to be less likely to vary under conditions that affect the expression of 
mRNAs, since they are transcribed by a distinct RNA polymerase. 18S rRNA has 
been described as a preferable internal control and most widely used as a 
housekeeping gene (Thellin et al., 1999). It is expressed at constant levels in normal 
liver versus liver metastasis (Blanquicett et al., 2002). It is also stably expressed in 
various cancer tissues which may result from its lack of involvement in cellular 
metabolism (Finnegan et al., 1993). However, other studies have shown that 18S 
rRNA is not a suitable control as it can be regulated (Solanas et al., 2001) and its 
synthesis is independent from synthesis of mRNA (Radonic et al., 2004). Our study 
also showed that 18S rRNA can be affected by trichostatin A (TSA) at least in 
prostate and breast tissue and probably in other tissues as well, hence we would not 
recommend 18S rRNA as a suitable housekeeping gene under the effects of histone 
deacetylase inhibitors (HDACi) such as trichostatin A (TSA).  
            β actin mRNA remains a widely used housekeeping gene internal control in 
molecular biology (Bernard et al., 1999), despite the fact that many studies have 
reported its cell cycle dependent expression pattern and regulation in specific 
circumstances. Some studies have also questioned the use of β actin mRNA as 
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 suitable internal control in RT-PCR since it does not satisfy certain basic 
requirements for application as a housekeeping gene (Serazin-Leroy et al., 1998; 
Yamada et al., 1997). Further, some studies have specifically shown that using β actin 
mRNA as an internal control can detrimentally affect the accuracy of RT-PCR results 
(Selvey et al., 2001). Similar to 18S rRNA, our study showed that β actin mRNA can 
also be regulated by trichostatin A (TSA) at least in prostate and breast tissue and 
probably in other tissues as well. Thus, we would not recommend β actin mRNA as 
suitable housekeeping gene with the use of trichostatin A (TSA).  
            Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is a key enzyme in 
glycolysis, which makes it an abundant RNA species for use as a potential internal 
RNA standard. This housekeeping gene is constitutively expressed in many tissues. 
However, wide variation in GAPDH expression levels have been observed in tissues 
at different developmental stages (Oikarinen et al., 1991), in cells treated with insulin 
(Nasrin et al., 1990), dexamethasone (Oikarinen et al., 1991), mitogens (Rao et al., 
1990) as well as virally transformed or oncogene-transfected fibroblasts (Bhatia et al., 
1994). Different tissue types exhibited marked differences in the expression of 
GAPDH gene. Furthermore, within the same tissue, GAPDH expression was up-
regulated in the presence of inflammation or malignant transformation (Jesnowski et 
al., 2002). The up-regulated expression levels of GAPDH have been previously 
reported in human pancreatic or colon adenocarcinoma (Schek et al., 1988). In tumor 
cells this could be due to an increase in glycolysis and glucose turnover. Further, 
GAPDH mRNA levels were up-regulated in the presence of hypoxia and by hypoxia 
inducible factor 1 (HIF-1) (Zhong and Simons, 1999). Moreover, GAPDH is 
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 pathologically implicated in neurodegeneration and apoptosis (Tatton et al., 2000). 
Our study showed that GAPDH mRNA can also be regulated by trichostatin A (TSA) 
at least in prostate and breast tissue and probably in other tissues as well. Thus, we 
would not recommend GAPDH mRNA as a suitable housekeeping gene with the use 
of trichostatin A (TSA).  
            Lastly we studied expression of the ribosomal highly basic 23-kDa protein (rb 
23-kDa, RPL13A) following trichostatin A (TSA) treatment. Previous studies have 
shown that the expression of the gene for the ribosomal highly basic 23-kDa protein 
(RPL13A) was remarkably constant between different tissue types (Jesnowski et al., 
2002). Furthermore, its expression was not affected by malignant transformation or 
inflammation in the same tissue in contrast to GAPDH (Jesnowski et al., 2002). One 
research group recommended RPL13A as a standard for normalization for at least the 
pancreas and prostate (Jesnowski et al., 2002). In our study, the expression of this 
gene was very stable following TSA treatment.  
            The stable and non-regulated expression of housekeeping genes is critical for 
accurate interpretation of RT-PCR results. Thus, it is essential to choose proper 
housekeeping genes when normalizing RNA concentrations (Rubie et al., 2005). Our 
study supports the notion that no one housekeeping gene is perfect under all 
experimental conditions, and that it is necessary to characterize the suitability of 
various housekeeping genes to serve as internal controls under particular 
experimental conditions. In conclusion, we recommend the use of the ribosomal 
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 highly basic 23-kDa protein (RPL13A) as a suitable standard for normalization with 
the use of histone deacetylase inhibitors (HDACi) such as trichostatin A (TSA).  
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 CHAPTER IV 
MECHANISM OF HAPLOINSUFFICIENT PROSTATE TUMOR 
SUPPRESSION AND ROLE FOR CHROMATIN ACCESSIBILITY 
 
 
Introduction: 
 
            As discussed earlier, transcription factor haploinsufficiency is a predisposing 
factor to a wide variety of disorders including cancer (Seidman and Seidman, 2002), 
but the precise mechanisms involved have remained elusive. We have established a 
mouse model of prostate tumor initiation due to haploinsufficiency of the 
homeodomain transcription factor Nkx3.1 (Abdulkadir et al., 2002; Magee et al., 
2003), which provided us with a unique opportunity for deciphering the mechanisms 
of transcription factor haploinsufficiency. In Nkx3.1-mutant mice, loss of even a 
single allele of the tumor suppressor Nkx3.1 stochastically inactivates the expression 
of a class of dosage-sensitive target genes (Magee et al., 2003). Interestingly, some 
Nkx3.1 target genes, such as intelectin/omentin, were exquisitely sensitive to a 
reduction in Nkx3.1 dose, while others such as probasin were only slightly affected 
(Magee et al., 2003). These results are consistent with a model of haploinsufficient 
tumor suppression in which reduction in Nkx3.1 dosage increases the probability of 
complete loss of expression of select target genes in prostate epithelial cells.  
            Here, we show that dosage-sensitivity of Nkx3.1 target genes is largely 
dictated by the differential histone H3/H4 acetylation states and Nkx3.1 occupancy at 
the target gene loci. In Nkx3.1+/- prostates, the dosage-insensitive gene probasin was 
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 hyperacetylated in its regulatory region, bound by Nkx3.1 and expressed. In contrast, 
the dosage-sensitive target intelectin was hypoacetylated, not bound by Nkx3.1 and 
silenced. Importantly, inducing histone acetylation with the histone deacetylase 
inhibitor, Trichostatin-A, allowed binding of Nkx3.1 and reactivation of dosage-
sensitive target gene expression in Nkx3.1+/- cells. We incorporated our findings into 
a mathematical model of Nkx3.1 gene regulation that predicts the involvement of 
Nkx3.1 in chromatin remodeling. We subsequently showed that Nkx3.1 is indeed 
involved in setting target gene histone acetylation levels through interactions with the 
histone acetyltransferase P/CAF (p300/CBP-associated factor).  
            In conclusion, our results reveal how the interplay between transcription 
factor dosage and chromatin affects target gene expression in tumor initiation. We 
demonstrate the importance of chromatin accessibility in dosage-sensitive and 
stochastic gene regulation and provide a mechanistic basis for haploinsufficient tumor 
suppression by Nkx3.1. 
 
 
 
 
 
 
 
 
 
 90
 Results and Discussion: 
 
Differential histone H3/H4 acetylation at the dosage-sensitive and dosage-
insensitive target gene loci 
We reasoned that Nkx3.1 dosage-sensitive and stochastic gene regulation may 
be mediated by the differential chromatin accessibilities of target gene loci. To 
investigate this, we examined the histone H3/H4 acetylation states of the promoter 
regions of two representative target genes in mouse prostate: intelectin and probasin 
(Magee et al., 2003). Probasin is a prostate specific differentiation marker (Kasper 
and Matusik, 2000) that is insensitive to Nkx3.1 dosage, while intelectin is a D-
galactosyl specific lectin that is also known as omentin, an adipocytokine (Tsuji et al., 
2001) (Schaffler et al., 2005). Intelectin shows exquisite sensitivity to Nkx3.1 dosage, 
with its expression in Nkx3.1+/- cells approximating the levels seen in Nkx3.1-/- cells 
(Magee et al., 2003). We used chromatin immunoprecipitation assays (ChIP)  to 
profile the histone H3 and H4 acetylation patterns in the 2-kb regions of the intelectin 
and probasin promoters in Nkx3.1-mutant mouse prostate tissues (Figure 27A,B). The 
intelectin promoter showed higher levels of histone H3 and H4 acetylation in 
Nkx3.1+/+ mice compared to Nkx3.1+/- or Nkx3.1-/- animals. In particular, we observed 
the maximum level of acetylation in a region (Int5) that was subsequently found to 
contain a consensus Nkx3.1 binding site (TAAGTG) (Steadman et al., 2000) by 
sequence analysis (Figure 27A). By contrast, on the probasin promoter, H3 and H4 
acetylation levels were high in Nkx3.1+/+ and Nkx3.1+/- mice and low in Nkx3.1-/- 
mice (Figure 27B). Thus expression of intelectin and probasin correlated with the 
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 overall histone H3/H4 acetylation states of their promoter regions in mice of various 
genotypes.  
 
Differential Nkx3.1 occupancy at the dosage-sensitive and dosage-insensitive 
target gene loci 
We examined in vivo binding of Nkx3.1 at the intelectin and probasin 
promoters in Nkx3.1-mutant mice by ChIP. Nkx3.1 was bound at the Int5 region of 
the intelectin promoter in Nkx3.1+/+ but not in Nkx3.1+/- mice, while Nkx3.1 binding 
to the Pbn1 region of the probasin promoter (containing a consensus Nkx3.1 site) was 
observed in both Nkx3.1+/+ and Nkx3.1+/- mice (Figure 28). We used a mouse 
androgen receptor promoter region containing a consensus Nkx3.1 binding site (AR) 
as a positive control (Lei et al., 2006) for Nkx3.1 ChIP while Int2 and Pbn4 regions 
(which do not contain Nkx3.1 consensus) served as negative controls. Thus 
expression of intelectin and probasin correlated with the Nkx3.1 occupancy in mice 
of various genotypes.  
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Figure 27. Dosage-sensitive and dosage-insensitive Nkx3.1 target gene loci show 
differential histone H3/H4 acetylation states: (A, B) ChIP analysis on prostate 
tissues from Nkx3.1-mutant mice show enrichment of acetylated histone H3 (Ac-H3) 
and acetylated histone H4 (Ac-H4) in the 2-Kb region of the intelectin and probasin 
promoters respectively. Schematics of the promoters with locations of quantitative 
PCR primers and putative Nkx3.1 binding sites (TAAGTG- red boxes) are shown 
below. ChIP values are represented as fold enrichments and calculated as [IP Ab/ 
Input Ab] / [IP IgG/ Input IgG]. Results are presented as Mean ± SD (N=6 per 
genotype).  
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Figure 28. Dosage-sensitive and dosage-insensitive Nkx3.1 target gene loci 
show differential Nkx3.1 occupancy in vivo: In vivo binding of Nkx3.1 to 
consensus sites on the intelectin (Int5) and probasin (Pbn1) promoters in Nkx3.1-
mutant mouse prostates by ChIP analysis. A mouse androgen receptor promoter 
region containing a consensus Nkx3.1 binding site (AR) was used as a positive 
control while Int2 and Pbn4 regions served as negative controls. Results are 
presented as Mean ± SD (N=6 per genotype). 
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 Induction of histone hyperacetylation with a HDAC inhibitor, TSA in Nkx3.1+/- 
mouse prostates 
            Our results thus far indicate that in Nkx3.1+/- prostate cells, the probasin 
promoter is hyperacetylated at histones H3/H4, resulting in an “open” chromatin 
configuration that allows Nkx3.1 binding and activation of gene expression.  The 
intelectin promoter on the other hand is in a hypoacetylated, “closed” chromatin state 
which precludes Nkx3.1 binding and gene activation. If so, then increasing chromatin 
accessibility by inducing histone H3/H4 hyperacetylation might allow Nkx3.1 
binding to the intelectin promoter and gene activation in Nkx3.1 heterozygous cells. 
To ascertain this, we treated mouse prostate tissue explants with the histone 
deacetylase inhibitor Trichostatin-A (TSA) (Yoshida et al., 1995). The efficacy of our 
treatment regimen was evident from results of western blot analyses for acetylated 
histone H3 (Figure 29 upper panel). TSA treatment did not have a discernible effect 
on Nkx3.1 protein expression (Figure 29 lower panel).  
            ChIP analysis of the intelectin promoter indicates that TSA treatment led to a 
significant increase in H3/H4 acetylation in Nkx3.1+/- mouse prostates, particularly in 
the Int5 region (Figure 30B and 30D). Notably, the levels of histone H3 acetylation 
observed at the Int5 region in Nkx3.1+/- mice after TSA treatment approximate the 
baseline levels seen in Nkx3.1+/+ mice (Figure 30B). By contrast, TSA treatment had 
modest or minimal effects on histone H3/H4 acetylation at the intelectin promoter in 
Nkx3.1+/+ and Nkx3.1-/- mice or the probasin promoter in all genotypes (Figure 30B, 
30C and Figure 30E). These results support the notion that acetylation is a dynamic 
process and there may be a limit to the maximum acetylation achievable at any 
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 promoter. They also suggest that Nkx3.1 may be involved in setting the histone 
H3/H4 acetylation states of its target genes.  
 
 
Figure 29. The histone deacetylase inhibitor, trichostatin A (TSA) induces 
histone acetylation in prostate explants: Western blot analyses with Nkx3.1- 
mutant mice prostate tissue explants following TSA treatment show significant 
increase in the Ac-H3 protein levels (upper panel). Total histone H3 was used as 
a loading control (middle panel). Notably, TSA treatment did not affect Nkx3.1 
protein expression (lower panel). 
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Figure 30. The histone deacetylase inhibitor, trichostatin A (TSA) induces 
histone acetylation at the dosage-sensitive gene loci in Nkx3.1+/- mouse 
prostate explants: (B, C) Prostate tissue ChIP assays for Ac-H3 on the intelectin 
and probasin promoters after TSA treatment. Note the significant increase in Ac-
H3 enrichment on the intelectin promoter particularly in the region of the Nkx3.1 
consensus site (Int5) in Nkx3.1+/- mice. (D, E) Prostate tissue ChIP assays for Ac-
H4 on the intelectin and probasin promoters after TSA treatment demonstrate the 
significant increase in Ac-H4 enrichment on the intelectin promoter particularly 
in the region Int5 in Nkx3.1+/- mice. Results are presented as Mean ± SD (N=6 
per genotype). 
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 Induction of histone hyperacetylation with TSA allows Nkx3.1 binding and 
reactivation of dosage-sensitive target gene expression in Nkx3.1+/- mouse 
prostates 
Using ChIP, we next showed that TSA treatment promotes the binding of 
Nkx3.1 to the Int5 region but not a control region in Nkx3.1+/- mice (Figure 31). 
Importantly, TSA treatment also significantly induced intelectin mRNA expression in 
Nkx3.1+/- mice as assessed by quantitative RT-PCR (Figure 32 upper panel). The 
expression of another dosage-sensitive Nkx3.1 target gene, Pdzk1, was also induced 
by TSA treatment in Nkx3.1+/- mice (Figure 32 upper panel), while the expression of 
the dosage-insensitive genes probasin and Sel1L (Magee et al., 2003) remained 
largely unaffected (Figure 32 lower panel). Notably, none of these genes was 
reactivated by TSA treatment in Nkx3.1-/- mice, emphasizing the requirement for 
Nkx3.1 in gene induction. We note that both intelectin and Pdzk1 were induced by 
TSA in Nkx3.1+/- mice to levels 3 to 4 fold above their respective expression levels in 
wild type mice, and that TSA treatment did not lead to a further increase in the 
expression of any of the genes tested in Nkx3.1+/+ prostates.  
            In addition to histone modifications, DNA methylation is another common 
epigenetic event important for regulating gene expression (Jones and Baylin, 2002). 
Hence, we investigated the possible involvement of DNA methylation in Nkx3.1 
target gene regulation by using the DNA methyltransferase inhibitor, 5-azacytidine 
(Groudine et al., 1981). Unlike TSA, treatment with 5-azacytidine did not have 
consistent effects on the expression of dosage-sensitive versus dosage-insensitive 
target genes (Figure 32). In our prostate explant experiments, longer period of 
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 treatment of 5-azacytidine could not be tested due to toxicity effects. Reactivation of 
dosage-sensitive target genes by TSA emphasizes the role of histone acetylation in 
the regulation of these Nkx3.1 target genes. These results point to the chromatin 
accessibility of target gene loci as a major determining factor in the response of target 
genes to reduced dosages of activating transcription factors. The ability to restore the 
expression of dosage-sensitive genes with HDAC inhibitors may have important 
therapeutic implications for disorders due to haploinsufficiency of transcription 
factors. 
 
 
Figure 31. TSA treatment promotes Nkx3.1 binding in vivo in Nkx3.1+/- 
mouse prostate explants: ChIP assays on the intelectin promoter show Nkx3.1 
binding to Int5 site but not Int2 control region following TSA treatment in 
Nkx3.1+/- mice. Results are presented as Mean ± SD from N ≥ 4.  
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Figure 32. The HDAC inhibitor, TSA, reactivates dosage-sensitive target gene 
expression in Nkx3.1+/- mouse prostate explants: Quantitative RT-PCR analysis for 
Nkx3.1 target gene expression following TSA treatment. Dosage-sensitive mRNAs 
like intelectin and Pdzk1 (upper panel) were significantly up-regulated in TSA-
treated Nkx3.1+/- mice prostate explants compared to dosage-insensitive targets like 
probasin and Sel1L (lower panel). 5-Azacytidine (Azacyt), a DNA hypo-methylating 
agent was used as additional control (N=3 per genotype). Results are presented as 
Mean ± SD. **, p < 0.05. 
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 Table 10. Primers used for ChIP assays and qRT-PCR 
 
ChIP Assay Primer Sequence 
 
Int1 
 
Int2 
 
Int3 
 
Int4 
 
Int5 
 
Int6 
 
Int7 
 
Int8 
 
Int9 
 
Pbn1 
 
Pbn2 
 
Pbn3 
 
Pbn4 
 
Pbn5 
 
Pbn6 
 
 
F: 5’- GGACACTATGCCCCTCCTTAG-3’ 
R: 5’-CAGCGTTTGGATGCTGATTA-3’ 
F: 5’- CGAAAGGACCCAGATGTAGC-3’ 
R: 5’-GCCCTGTGATCCATCCATTA-3’ 
F: 5’- CCAAGGAGCTAAAGGGATCTG-3’ 
R: 5’-CCAATGGACCTCTCTTTCCA-3’ 
F: 5’-GAATTCCAGGGCCAAAAAG-3’ 
R: 5’-TTAGCTCATTTACATTTCCAATGC-3’ 
F: 5’-GATTGAAGAAGATAGCCCATGC-3’ 
R: 5’-TTGGGTTTTGAAAGTTTCTTATTTG-3’ 
F: 5’-AAAGGATGTCATTTCCTTCTGC-3’ 
R: 5’-TTTCTTCCTTATCAATCCCTAAGC-3’ 
F: 5’-TGCAGTGCATGCCTTTAATC-3’ 
R: 5’-CACGGAGGACTACTTTTCCAA-3’ 
F: 5’-CACACCCATTGTGATTGTGC-3’ 
R: 5’-TGGTGGTGGGTTTTGAGATT-3’ 
F: 5’-ATTTGTCTTTTAGGGCCCACT-3’ 
R: 5’-GGTCCTTTTATGGGGAAAGC-3’ 
F: 5’-TGGTATTTCCTACTGCCAGACA-3’ 
R: 5’-TTATGTGCAGTCATGAGATTGTC-3’ 
F: 5’-ATGCCACTTTGAGGAATTGG-3’ 
R: 5’-AAGGTCACTGTTTCGGAGGT-3’ 
F: 5’-TTCCTTCTGTATGTTGCATTTTC-3’ 
R: 5’-CGCACATCTCAGGAACACAG-3’ 
F: 5’-TCAGCACAGGTTCCTGAAAA-3’ 
R: 5’-TTGAGTTCATGGGTGTGTGG-3’ 
F: 5’-TTGTCGTGATTGACAAGCTG-3’ 
R: 5’-TGGAACTGGAGGTTCTAGCC-3’ 
F: 5’-GCCATGTTTTTGGTCATGTG-3’ 
R: 5’-TGGAAGAATATCAAGTCTGACCA-3’ 
 
RT-PCR Primer Sequence 
 
mIntelectin1 
 
mPdzk1 
 
mSel1L 
 
mProbasin 
 
hINTELECTIN1 
 
hPDZK1 
 
hSEL1L 
 
hPSA 
 
hANGIOPOIETIN 2 
 
hNKX3.1 
 
 
F: 5’-AGCGGCCAGTGCCTTGT-3’ 
R: 5’-ACCGATGCAGTGATGTTCAGTATT-3’ 
F: 5’-TCTGCGGAGTCCGAGCAT-3’ 
R: 5’-GAGTGTGAGGCTGTGCTGAGAGT-3’ 
F: 5’-AGAAAACAGCCTTAACCAACTTGAG-3’ 
R: 5’-TCCGGGAAGCAACGAATCTA-3’ 
F: 5’-CTCCTGCTCACACTGCATGTG-3’ 
R: 5’-CCAAGGCCCGTCAATCTTC-3’ 
F: 5’-GGAGAAGGAAAGTGTTGGACTGA-3’ 
R: 5’-GGCGTCGCCAAAATCATAGA-3’ 
F: 5’-CCACTGGAAACCATTCACCAT-3’ 
R: 5’-TCTGCAATAGCCGCCTGTAA-3’ 
F: 5’-GCGTGATTCACTTTAGCCTGATTAT-3’ 
R: 5’-TAGTCTAAATGTTACTGTGTGGTACG-3’ 
F: 5’-TGAGAAACCTGAGATTAGGA-3’ 
R: 5’-ATCTCTCTCAGATCCAGGCT-3’ 
F: 5’-GACTTCCAGAGGACGTGGAAAG-3’ 
R: 5’-CTCATTGCCCAGCCAGTACTC-3’ 
F: 5’-GCAGAGACCGAGCCAGAAA-3’ 
R: 5’-GAACTTCCTCTCCAACTCGATCA-3’ 
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 A mathematical model of gene activation by Nkx3.1 
            To gain further insights into the interactions between Nkx3.1 dosage and 
chromatin remodeling in target gene regulation, we incorporated our current results 
and earlier findings (Magee et al., 2003) into a mathematical model of gene activation 
by Nkx3.1 (Figure 33A). According to this model, a target gene can exist in an 
inactive/closed chromatin (hypoacetylated state) or an active/open chromatin 
(hyperacetylated state) competent for transcription. Due to the fact that we observed 
reduced histone H3/H4 acetylation in Nkx3.1 null cells and focal hyperacetylation in 
a region containing the Nkx3.1 binding site on the intelectin promoter, we assumed in 
the model that Nkx3.1 interacts with a histone acetyltransferase (8) and influences the 
active to inactive gene ratio. TSA also affects this ratio by inhibiting the transition 
from the active to the inactive state due to its known ability to inhibit HDACs. In 
addition, we assume that Nkx3.1 directly affects the rate of transcription from the 
active gene. Input values for levels of Nkx3.1 in Nkx3.1+/+ and Nkx3.1+/- mice were 
obtained from experimental measurements (Magee et al., 2003). Further details of the 
model and its representation by a set of ordinary differential equations can be found 
in the materials and methods section. We find that simulations from this model for the 
expression of intelectin and probasin in the presence of one or two Nkx3.1 alleles 
(Figure 33B and 33C) closely paralleled experimental findings for probasin and 
intelectin mRNA expression in a castration/testosterone replacement paradigm in 
Nkx3.1+/+ and Nkx3.1+/- mice (Magee et al., 2003). We also modeled the effects of 
TSA. Simulations for the effects of TSA showed the most significant induction over 
baseline in the case of intelectin in the presence of one Nkx3.1 allele (Figure 33D-G), 
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 similar to the experimental observations for Nkx3.1+/- mice (see Figure 32), although 
the fold induction observed in the simulation  is not as high as that observed 
experimentally. The mathematical relationship between gene inactivation rate 
constant, K2, TSA, and the initial ratio of active to inactive genes is shown in Figure 
34. Overall, the modeling results closely simulated experimental observations 
regarding dosage-sensitive target gene regulation. We have not modeled stochastic 
variations in Nkx3.1 itself as done by others (Karmakar and Bose, 2006); rather, in 
our model the initial ratio of active to inactive genes which reflects chromatin 
accessibility/acetylation introduces a stochastic component into the model and is a 
major determinant of the dynamics of the model.  
                                A 
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Figure 33. A mathematical model of gene activation by Nkx3.1: (A) Network 
depiction of gene activation by Nkx3.1. TSA is shown as inhibiting the transition 
from active gene (hyperacetylated, open chromatin) to inactive gene (hypoacetylated, 
closed chromatin). Nkx3.1 levels are derived from experimental observations (Magee 
at el., 2003). A histone acetyltransferase, HAT complexes with Nkx3.1 and is 
assumed to be constitutively synthesized. (B, C) Results of simulations showing 
expression levels of intelectin and probasin in Nkx3.1+/+ and Nkx3.1+/- mice. (D-G) 
Results of simulations showing the effects of TSA on target gene expression. Red 
lines, +TSA; Blue lines, -TSA 
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Figure 34. Graph showing effect of TSA on gene activation: The mathematical 
relationship between the rate constant K2 which controls the rate at which an active 
gene is inactivated, the level of TSA and the initial ratio of active to inactive genes, 
R0. This is a plot of Equation 10 in the Methods section. 
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 Nkx3.1 associates with, and recruits the histone acetyltransferase PCAF to 
chromatin 
            The modeling results coupled with our results showing reduced histone 
acetylation at the probasin and intelectin promoters in Nkx3.1-deficient mice 
prompted us to examine the possibility that Nkx3.1 is associated with histone 
acetyltransferase activity. Using co-immunoprecipitation analyses, we found evidence 
of interaction between Nkx3.1 and PCAF in human prostate cancer cells (LNCaP) 
and mouse prostate tissue (Figure 35).  
 
 
 
Figure 35. Nkx3.1 interacts with histone acetyl transferase, PCAF in vivo: Co-
immunoprecipitation assays demonstrate association of Nkx3.1 and PCAF in 
LNCaP cells and mouse prostate tissue. Lysates were immunoprecipitated with 
anti-Nkx3.1 antibody and then blotted for anti-PCAF antibody (upper panel) or 
vice versa (lower panel). 
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               Next we assessed whether Nkx3.1 recruits PCAF to target gene promoters. 
ChIP assays with mouse prostate tissues showed PCAF binding to the Nkx3.1 
consensus sites of both the intelectin (Int5 in Nkx3.1+/+) and probasin promoters 
(Pbn1 in Nkx3.1+/+ and Nkx3.1+/-) (Figure 36). These results are consistent with the 
‘gene-specific targeting model’ of histone acetylation (Struhl, 1998) which implies 
recruitment of HATs to particular promoter regions by sequence-specific DNA 
binding proteins. We also observed PCAF binding at the Pbn4 control region that 
does not contain an Nkx3.1 consensus in Nkx3.1+/+ and Nkx3.1+/- mice, presumably 
due to the ability of PCAF to bind to acetylated histones through its bromodomain 
(Dhalluin et al., 1999).  
 
 
Figure 36. Nkx3.1 recruits PCAF at the chromatin: ChIP assays on the intelectin (left) 
and probasin (right) promoters demonstrate the recruitment of PCAF to the Nkx3.1 DNA 
binding site. Results are presented as Mean ± SD from N ≥ 4. 
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              As we observed Nkx3.1 binding to the intelectin promoter in Nkx3.1+/- mice 
following TSA treatment (see Figure 31), we sought to determine if Nkx3.1 can 
recruit PCAF to the intelectin promoter under these conditions as well. ChIP assays 
established that PCAF was recruited to the Int5 region in Nkx3.1+/- mice after TSA 
treatment (Figure 37). Hyperacetylation in the Int5 region after TSA treatment could 
have also contributed to PCAF recruitment to this site, in addition to the interaction 
with Nkx3.1. Nevertheless, failure to observe recruitment of PCAF at a control region 
(Int2) after TSA treatment suggests that Nkx3.1 is involved in the targeted 
recruitment of PCAF to the Nkx3.1 binding site (Int5) on the intelectin promoter.  
 
 
Figure 37. TSA treatment leads to recruitment of PCAF at the intelectin promoter in 
Nkx3.1+/- mice: Recruitment of PCAF to the Nkx3.1 site (Int5) on the intelectin promoter 
in Nkx3.1+/- mice following TSA treatment by ChIP analysis. Results are presented as 
Mean ± SD from N=4. 
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              To establish whether Nkx3.1 and PCAF can form a complex at the same 
region of DNA on the intelectin promoter, we performed two-step ChIP assays. The 
results indicate that Nkx3.1 and PCAF were bound at the same Int5 region (Figure 
38). Thus Nkx3.1 can recruit PCAF to DNA in a dosage-sensitive and promoter-
specific manner, likely to set histone acetylation states of target genes. Nkx3.1 can 
both repress and activate transcription, and has been reported to interact with HDAC1 
(Lei et al., 2006), raising the possibility that differential complex formation with 
HATs or HDACs may determine whether Nkx3.1 activates or represses a target gene. 
 
 
 
 
Figure 38. Nkx3.1 and PCAF form complex at the chromatin: Two-step ChIP 
assays demonstrate that Nkx3.1 and PCAF can interact at the Nkx3.1 site (Int5) on the 
intelectin promoter in Nkx3.1+/+ mice. Results are presented as Mean ± SD from N=4. 
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 Conclusions: 
             In summary, based on our results we propose a chromatin mechanism for 
Nkx3.1 haploinsufficiency in prostate tumor initiation. We propose a model (Figure 
39) whereby dosage-sensitive and dosage-insensitive Nkx3.1 target gene loci show 
differential chromatin accessibilities, due to differential Nkx3.1/PCAF occupancy. 
Nkx3.1/PCAF are involved in setting differential histone acetylation states and target 
gene expression patterns. Our results provide an example of how a genetic lesion 
(haploid loss of the Nkx3.1 tumor suppressor) can engender epigenetic changes 
(alterations in histone H3/H4 acetylation) that selectively inactivate a dosage-
sensitive target gene important for suppressing tumorigenicity. This mechanism may 
be applicable to other disorders caused by transcription factor haploinsufficiency. The 
reduced chromatin accessibility of some target genes can lead to their selective 
inactivation in heterozygous cells, with attendant pathology. 
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Figure 39. Dosage-sensitive, stochastic Nkx3.1 target gene activation model: A 
schematic representation of the dosage-sensitive, stochastic Nkx3.1 target gene activation 
model. The differential chromatin states, Nkx3.1 occupancy and PCAF recruitment at the 
probasin (dosage-insensitive) and intelectin (dosage-sensitive) promoters in Nkx3.1-
mutant mice are illustrated. Note the effects of inducing histone acetylation by 
Trichostatin A (TSA), at the intelectin promoter in Nkx3.1+/- animals. 
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 CHAPTER V 
FUNCTIONAL ANALYSIS OF NKX3.1 TARGET GENE INTELECTIN/ 
OMENTIN IN PROSTATE CANCER 
 
 
Introduction: 
            The Nkx3.1 model of haploinsufficiency in prostate tumor initiation 
(Abdulkadir, 2005; Magee et al., 2003) posits that in Nkx3.1 heterozygous cells, 
selective inactivation of dosage-sensitive target genes could confer a growth 
advantage. This would lead to a clonal expansion of the heterozygous cells, providing 
a larger target cell population for additional genetic mutations. A key unproven 
assumption of this model is that some dosage-sensitive Nkx3.1 targets have prostate 
tumor suppressive properties. In my dissertation work, we functionally characterized 
the dosage-sensitive target intelectin / omentin to explore its role in the differentiation 
and immortalization pathways involved in prostate tumorigenesis.  
             Human intelectin (hIntL) is a soluble lectin that recognizes galactofuranose in 
carbohydrate chains of bacterial cell wall and plays a role in the recognition of 
bacteria-specific components in the host (Tsuji et al., 2001). The mature hIntL is a 
secretory glycoprotein consisting of 295 amino acids and N-linked oligosaccharides. 
The basic structural unit of hIntL consists of a 120-kDa homotrimer in which 40-kDa 
polypeptides are bridged by disulfide bonds. The hIntL gene consists of 8 exons 
located on chromosome 1q21.3 and shows high levels of homology with mouse 
intelectin. Previous mRNA study has identified that intelectin is expressed in the 
heart, small intestine, colon, and thymus (Tsuji et al., 2001).   
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             Very recently, sequence analysis studies have revealed 100 % identity 
between human intelectin and omentin (Schaffler et al., 2005), an adipocytokine 
which profoundly affects insulin sensitivity and plays significant role in obesity, 
insulin resistance and cardiovascular disease (Kralisch et al., 2005). Intelectin is a 
mammalian Ca2+ -dependent D-galactosyl-specific lectin which is structurally related 
to the intestinal lactoferrin receptor. It is expressed in paneth and goblet cells of the 
small intestine where it plays protective role in the innate immune response against 
various parasite infection (Wrackmeyer et al., 2006). 
            The role of intelectin in cancer however, is not very well studied. Wali and 
colleagues reported that the intelectin gene is over-expressed in malignant pleural 
mesothelioma tumor samples compared to autologous normal epithelium by serial 
analysis of gene expression (SAGE) (Wali et al., 2005). Apart from this study the 
functional relevance of the intelectin gene in other cancers has not yet been explored. 
We have examined the role of intelectin in prostate tissue and we present strong 
evidence suggesting that intelectin has a tumor suppressor-like activity in prostate 
cancer. 
 
Results and Discussion: 
 
Establishment of shRNA mediated stable knockdown cell lines of NKX3.1 and 
Intelectin 
           We examined the role of intelectin using LNCaP prostate cells which express 
appreciable amounts of NKX3.1 and intelectin. We used a lentiviral mediated shRNA 
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 approach to stably knockdown NKX3.1 and intelectin in LNCaP cells and confirmed 
shRNA mediated knockdown efficiency by western blot analysis. Our results showed 
that both NKX3.1 and intelectin proteins were significantly knocked down in LNCaP 
cells (Figure 40A and 40B). Consistent with it being a dosage-sensitive NKX3.1 
target, the expression of intelectin was dramatically reduced in NKX3.1 knockdown 
clones (Figure 40A). In contrast, NKX3.1 protein levels remained unaffected in 
intelectin knockdown clones (Figure 40B).  
  
 
Figure 40. Establishment of stable knockdown cells of NKX3.1 and intelectin: (A) 
Western blot analyses to confirm the stable knockdown of NKX3.1 protein levels in 
LNCaP prostate cells (upper panel). Note the reduced level of intelectin protein in 
NKX3.1 knockdown clones (middle panel). Actin was used as a loading control (lower 
panel). (B) Western blot analyses to confirm the stable knockdown of intelectin protein 
levels in LNCaP prostate cells (upper panel). NKX3.1 protein levels were unaffected in 
intelectin knockdown clones (middle panel). Actin was used as a loading control (lower 
panel). 
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 Altered NKX3.1 target gene expression in stable NKX3.1 knockdown cells 
kx3.1- 
A expression of negatively regulated 
            Magee and colleagues examined Nkx3.1 target gene expression in N
mutant mice and identified a spectrum of positively and negatively regulated target 
genes (Magee et al., 2003). We examined mRNA expression of NKX3.1 target genes 
in NKX3.1 knockdown LNCaP cells by qRT-PCR analysis (Figure 41). Our results 
showed that positively regulated target genes such as INTELECTIN, PDZK1, and 
SEL1L mRNA levels were significantly down-regulated (Figure 41B-D) in NKX3.1 
knockdown cells compared to control cells.  
            Moreover, we examined the mRN
NKX3.1 target genes such as PSA and ANGIOPOIETIN2. Interestingly, both PSA and 
ANGIOPOIETIN2 were significantly up-regulated in NKX3.1 knockdown cells 
compared to control cells (Figure 41E and 41F). These results are consistent with the 
gene profiling microarray data from Nkx3.1-mutant mice (Magee et al., 2003). 
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Figure 41. Altered NKX3.1 target gene expression in stable NKX3.1 knockdown cells: 
Quantitative RT-PCR analysis for NKX3.1 target genes in stable NKX3.1 knockdown 
LNCaP cells. (A) NKX3.1 mRNA level was significantly reduced in NKX3.1 knockdown 
cells compared to control cells. (B-F) Significant reduction in the mRNA levels of positively 
regulated genes such as INTELECTIN (B), PDZK1 (C) and SEL1L (D) was observed in 
NKX3.1 knockdown clones. PSA (E) and ANGIOPOIETIN 2 (F) are negatively regulated by 
NKX3.1 and their mRNA levels were significantly up-regulated in knockdown clones 
compared to control clones. 
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 The dosage-sensitive Nkx3.1 target gene intelectin suppresses prostate cell 
growth  
            To determine the effects of intelectin on prostate cell growth, we performed a 
series of in vitro proliferation assays. First we performed cell growth analysis and 
found that the proliferation rates of both the intelectin and NKX3.1 stable knockdown 
clones were significantly increased compared to control cells (Figure 42).  
 
 
             
 
Figure 42. Intelectin suppresses prostate cell growth in vitro: Cell growth analyses show 
the significant increase (**, p < 0.05) in growth of NKX3.1 and intelectin stable knockdown 
LNCaP cells compared to empty vector control. Two independent experiments in duplicates 
were performed and results are presented as Mean ± SD.  
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              Additionally, we examined the antiproliferative effects of intelectin by MTT 
assays in DU145 prostate cells which express very low intelectin endogenously 
(Figure 43: inset). Interestingly, our analysis revealed that cell viability was 
significantly decreased in cells transfected with intelectin/omentin compared to cells 
transfected with control vector (Figure 43). Furthermore, we rescued the growth 
phenotype in Nkx3.1 knockdown cells with low intelectin expression by exogenous 
intelectin (Figure 43). Thus, cell growth analysis and cell viability studies suggest that 
intelectin/omentin may have tumor suppressing ability in prostate cells.  
 
 
 
Figure 43. Intelectin inhibits prostate cell viability in vitro: MTT cell viability assays 
demonstrate the significant decrease (**, p < 0.05) in cell viability of DU145 and 
shNKX3.1-LNCaP cells with overexpression of intelectin /omentin compared to the empty 
control vector. Insets: Western blot analysis to demonstrate the transfection efficiency. Two 
independent experiments in quadruplicates were performed and results are presented as 
Mean ± SD.  
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 Intelectin / omentin is a bona-fide prostate tumor suppressor in vivo  
             We next examined the tumorigenicity of the intelectin knockdown cells by 
performing soft-agar colony formation assays. Consistent with the in vitro 
proliferation assays, increased colony formation was observed for both the intelectin 
and NKX3.1 knockdown clones compared to control cells (Figure 44) suggesting that 
intelectin has tumor suppressor-like activity in prostate cells.  
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Figure 44. Anchorage-independent growth in intelectin knockdown cells: Soft agar 
colony formation assays reveal increased anchorage-independent growth for NKX3.1 and 
intelectin knockdown LNCaP cells (*, p < 0.05). Representative fields are shown (2.5 x 
Magnification). The results are presented as Mean ± SD. 
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              To establish the tumor suppressor function of intelectin in vivo, we performed 
xenograft studies in immuno-compromised mice. We found that the tumors in mice 
injected with intelectin and NKX3.1 knockdown cells grew faster and to greater 
volumes than the tumors in mice injected with control cells (Figure 45). Mean tumor 
weight was also significantly greater in the intelectin and NKX3.1 knockdown group 
than the control group (Figure 46). These studies strongly support a tumor suppressor 
role for intelectin in prostate cells. 
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Figure 45. Intelectin shows a prostate tumor suppressor function in vivo: Xenograft 
studies demonstrate the in vivo tumor suppressor-like activity for intelectin in prostate 
cancer. Tumors from intelectin/shRNA (N=8) and NKX3.1/shRNA (N=6) LNCaP cells grew 
faster than the control group (N=6). 
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Figure 46. Intelectin is a bona-fide prostate tumor suppressor: Xenograft studies 
demonstrate the in vivo tumor suppressor-like activity for intelectin in prostate cancer.  
Note the significant increase in the mean tumor mass in intelectin and NKX3.1 
knockdown group compared to control group (top panel). Representative tumors from 
each group are shown in (bottom panel). The results are presented as Mean ± SD. 
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 Conclusions: 
            In conclusion, we provide evidence that Nkx3.1 target genes may have a 
functional significance in prostate tumorigenesis. Here, we performed a series of in 
vitro and in vivo experiments which indicate that the Nkx3.1 dosage-sensitive target, 
intelectin / omentin may have tumor suppressor-like activity in prostate. We observed 
that prostate cells deficient in intelectin / omentin demonstrate rapid proliferation 
rates and increased anchorage-independent cell growth. Furthermore, transfection of 
exogenous intelectin / omentin in prostate cells with low endogenous intelectin 
expression results in significantly decreased in cell viability. Consistent with our in 
vitro findings, Xenograft studies demonstrate that athymic mice injected with 
intelectin knockdown cells develop tumors at faster rates and at greater volumes 
compared to the control cells. Overall, our study strongly suggests a tumor suppressor 
like function for intelectin / omentin in prostate cancer in vivo. Furthermore, as this is 
the first piece of evidence for functional significance of Nkx3.1 targets, it opens new 
avenues to explore the functional relevance of other Nkx3.1 targets that may help to 
characterize the molecular pathways involved in prostate tumorigenesis.  
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 CHAPTER VI 
CELL CYCLE REGULATION BY NKX3.1 
 
 
Introduction: 
 
Delayed cell cycle exit in Nkx3.1-deficient mice 
            Nkx3.1-deficient mice develop prostatic hyperplasia that can progress to 
prostatic intraepithelial neoplasia (PIN) lesions over time (Abdulkadir et al., 2002); 
(Bhatia-Gaur et al., 1999). Further, conditional knockout Nkx3.1 mice also develop 
hyperplasia and PIN lesions which resemble to the human PIN lesions (Abdulkadir et 
al., 2002) suggesting that Nkx3.1 somehow establishes or maintains luminal epithelia 
in a growth arrested state. Magee and colleagues utilized the castration testosterone 
replacement (see Figure 9) and demonstrated that Nkx3.1 regulates the cell cycle exit 
of luminal epithelia during prostate regeneration. Nkx3.1-deficient luminal cells fail to 
appropriately exit the transient proliferation state (Magee et al., 2003). 
            To determine the effects of Nkx3.1 on growth arrest in the regenerating 
prostate, Magee and colleagues analyzed Ki-67 mRNA expression in Nkx3.1+/+, 
Nkx3.1+/- and Nkx3.1-/- prostates by RT-PCR. Ki-67 mRNA profiles showed that 
Nkx3.1+/- and Nkx3.1-/- mice exhibit an extended proliferative phase (Magee et al., 
2003). Next they counted the number of cells that incorporated Brdu at 3 and 7 days 
post-TR and found no difference in fraction of Brdu positive cells in Nkx3.1+/+, 
Nkx3.1+/- and Nkx3.1-/- at day 3. However, by day 7, the fraction of Brdu positive cells 
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 in Nkx3.1+/+ was dramatically reduced compared to the day 3, while a much larger 
population of cells continued to divide in Nkx3.1+/- and Nkx3.1-/- mice (Figure 47A-F). 
These results support the notion that Nkx3.1 regulates luminal cell exit from cell 
cycle, in other words, loss of one or both alleles of Nkx3.1 precludes timely 
withdrawal of luminal epithelia from cell cycle. Nevertheless, the underlying 
molecular mechanism behind this phenomenon has not been explored. We present 
some data which suggest that this may be mediated through potential Nkx3.1-
HDAC1-cyclin D/E pathway.                
 
KOWT 
BrDU 
  (3d) 
 E-cad
  (7d)  
Figure 47: Loss of Nkx3.1 results in extended periods of proliferation and 
luminal hyperplasia in prostate: [A-D] Brdu incorporation assays for cell 
proliferation at 3 (A,B) and 7 (C,D) days post-TR. Brdu: Red; E-cad: Green (luminal 
epithelial cell marker). [E-F] Note the percentages of Brdu incorporating cells at 3 
(E) and 7 (F) days in different genotypes. At day 7 cells from Nkx3.1+/- and Nkx3.1-/- 
prostates continue to divide and fail to exit cell cycle. [G-H] H&E staining showed 
dramatic hyperplasia in Nkx3.1-/- prostates (H) at 14 days post-TR relative to the 
Nkx3.1+/+ (G) (Adapted and modified from Magee et al., 2003 Cancer Cell). 
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 Role of HDAC1 in cell cycle regulation: 
           The histone deacetylase 1 (HDAC1) gene has been implicated in controlling 
the transcription of core cell cycle regulators, but the in vivo role of HDACs in cell 
cycle regulation is still not well understood. HDAC1 has been shown to be recruited 
by the Retinoblastoma (Rb) protein and related proteins to the promoters of several 
cell cycle genes (Zhang and Dean, 2001). Rb represses the transcription of cell cycle 
genes that contain E2F binding sites in their promoters and this repression is required 
for Rb-mediated growth suppression (Zhang et al., 1999). The recruitment of HDAC1 
by Rb leads to deacetylation of histones at target gene promoters (Luo et al., 1998) 
and inhibition of HDAC activity blocks Rb-mediated repression of genes activated at 
G1/S transition, including cyclin E (Zhang et al., 2000). 
            In contrast, some in vivo studies have indicated that HDACs can promote 
proliferation. Mouse embryos mutant for HDAC1 show an overall reduction of 
proliferation and decrease in cyclin-dependent kinase (CDK) activity and die before 
the stages of organogenesis (Lagger et al., 2002). Additionally studies in zebrafish 
found that hdac1 mutant can survive longer but display hindbrain underproliferation 
(Cunliffe, 2004). Lastly, HDAC inhibitors (HDACi) cause growth arrest in several 
tumors and are therefore targeted as a potential anticancer therapeutics. 
            Recently, Stadler and colleagues demonstrated that HDAC1 is cell-
autonomously required for cell cycle exit and differentiation in the retina of zebrafish 
(Stadler et al., 2005). To determine the role of hdac1 in the differentiation of 
zebrafish retina, the authors utilized BrdU incorporation and surprisingly found more 
proliferation in retina and optic stalk in the eyes of hdac1 mutants compared to wild 
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 type (Figure 48 A,B). The fraction of mitotic cells was assessed by anti-phospho-
histone H3 staining which was also elevated in hdac1 mutants (Figure 48 C,D).  
           Cyclin D and E are known to drive cell cycle progression in various 
organisms; hence Stadler and colleagues examined cyclin D1 and cyclin E2 RNA 
expression by in situ hybridization in hdac1 mutant retina (Stadler et al., 2005). 
Interestingly, cyclin D1 and E2 were expressed in wild type retina, but were down-
regulated in differentiating cells (Figure 48K,M). In contrast, expression of both 
cyclin D1 and E2 was failed to down-regulate and were strongly expressed in hdac1 
mutant retina (Figure 48L,N). These studies support the idea that HDAC1 is required 
for transcriptional repression of cyclin D1 and E2 and for cell cycle exit in zebrafish 
retina (Stadler et al., 2005). 
 
HDAC1 MutantWTHDAC1 MutantWT 
BrdU embryo 
   (72 hr PF) Cyclin D1
Cyclin E2
Anti-phospho-H3  
      IF-eyes  
Figure 48: Loss of hdac1 activity results in failure of retinal cells to exit the cell cycle: 
(A-B) Brdu incorporation in 72 h postfertilization (hpf) in wild type (A) or hdac1 mutants 
(B); (C-D) Anti-H3 immunofluoresence on cryosections of 72 hpf wild type (C) and hdac1 
mutants (D). (K-N) Whole mount in situ hybridization of cyclin D1 (K,L) and cyclin E2 
(M,N) RNA (Adapted and modified from Stadler et al., 2005 Develpomental Dynamics). 
 
 
 126
 Preliminary results and Discussion: 
 
Altered expression of cyclins in Nkx3.1-deficient mice 
           To investigate the molecular mechanism of cell cycle regulation by Nkx3.1, 
we first examined the expression of different cyclins including cyclin D1, cyclin E2, 
cyclin A2 and cyclin B1 in Nkx3.1-mutant mouse prostates by qRT-PCR analysis. 
Intriguingly, we found that cyclin D1 and cyclin E2 mRNA levels were significantly 
up-regulated in Nkx3.1+/- and Nkx3.1-/- prostates while cyclin A2 and cyclin B1 
mRNA levels remained unaffected (Figure 49).  
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Figure 49. Altered expression of cyclins in Nkx3.1-deficient mice: QRT-PCR 
analysis on Nkx3.1-mutant mice prostates indicate that cyclins D1 (A) and cyclin E2 
(B) mRNA are dramatically up-regulated (*P<0.05, **P<0.001)  in Nkx3.1-deficient 
mice compared to wild type mice while cyclin A2 (C) and cyclin B1 (D) mRNA 
remain largely unaffected. 
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             We further examined the expression of cyclins in LNCaP cells in which 
NKX3.1 was transiently knocked down. We found that cyclin E2 and cyclin A2 were 
significantly up-regulated while cyclin D1 and cyclin B1 remained unaffected (Figure 
50). 
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Figure 50. Altered expression of cyclins in response to siNKX3.1 in LNCaP cells: 
QRT-PCR analysis in either siGFP or siNKX3.1 LNCaP cells indicate that cyclins E2 
and cyclin A2 mRNA are dramatically up-regulated (*P<0.05, **P<0.001) upon 
NKX3.1 downregulation. Note that cyclin D1 and cyclin B1 mRNA remain unaffected. 
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 Differential HDAC expression in Nkx3.1-mutant mice 
            Histone deacetylases (HDACs) have been consistently linked to the cell cycle 
regulation. To our knowledge, HDAC expression in mouse prostate has not been yet 
studied, so we first examined the expression of different HDACs by quantitative RT-
PCR in Nkx3.1-mutant prostates. Our analysis revealed that HDAC1 and HDAC2 
were expressed abundantly in the wild type mouse prostate tissue. We found that 
HDAC3, HDAC5, HDAC6, HDAC7 and HDAC8 were expressed at low levels and 
HDAC9 was not expressed in wild type mouse prostate tissue (Figure 51). 
Interestingly, we observed that HDAC1 and HDAC2 expression was dramatically 
reduced in Nkx3.1+/- and Nkx3.1-/- prostates compared to their wild type levels. 
Furthermore, none of the other HDACs tested showed significant differences in their 
expression among different genotypes of Nkx3.1-mutant prostates (Figure 51). 
            Among different HDACs, HDAC1 has been shown to play significant role in 
the cell cycle exit in zebrafish visual system (Stadler et al., 2005). Magee and 
colleagues (Magee et al., 2003) provided evidence that prostate epithelia in Nkx3.1- 
deficient mice exhibit delayed cell cycle exit. Furthermore, we observed dramatic 
reduction in mRNA levels of HDAC1 in Nkx3.1-deficient prostates (Figure 51). 
These observations suggest that HDAC1 may play a critical role in delayed cell cycle 
exit of prostate epithelia in Nkx3.1-deficient mice. We therefore examined the 
HDAC1 protein expression in Nkx3.1-mutant mice prostate tissue by western blot 
analysis. Consistent with our mRNA data, western blot studies demonstrate that 
HDAC1 protein expression was significantly reduced in Nkx3.1+/- and Nkx3.1-/- 
prostates compared to the wild type expression (Figure 52). 
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Figure 51. Differential expression of HDACs in Nkx3.1-mutant prostate tissue: QRT-
PCR analysis demonstrates that HDAC1 and HDAC2 were abundantly expressed in wild 
type mouse prostate tissue. Note that HDAC1 and HDAC2 mRNA levels were dramatically 
reduced in Nkx3.1+/- and Nkx3.1-/- prostates compared to their wild type expression levels 
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Figure 52. HDAC1 protein expression in Nkx3.1-mutant prostate tissue: Western blot 
analysis to show HDAC1 (upper panel) and Nkx3.1 (middle panel) protein expression in 
Nkx3.1+/+, Nkx3.1+/- and Nkx3.1-/- prostates. Note that HDAC1 protein expression was 
markedly reduced in Nkx3.1+/- and Nkx3.1-/- prostates compared to the wild type expression.  
Actin (lower panel) was used as a loading control. 
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 Altered HDAC enzyme activity in Nkx3.1 -deficient prostates 
           QRT-PCR analysis coupled with western blot analysis indicates that HDAC1 
mRNA and protein expression is reduced in Nkx3.1-deficient prostates. To further 
explore the role of HDACs in cell cycle regulation in Nkx3.1-mutant mice, we 
examined the HDAC enzymatic activity using a HDAC colorimetric assay. Again 
consistent to the mRNA and protein studies, HDAC activity assays revealed that 
HDAC enzymatic activity was also significantly reduced in Nkx3.1+/- and Nkx3.1-/- 
mice prostates than the wild type activity level (Figure 53). 
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Figure 53. Altered HDAC enzyme activity in Nkx3.1-deficient prostates: HDAC 
activity assay demonstrate that HDAC enzymatic activity is significantly reduced in 
Nkx3.1+/- and Nkx3.1-/- prostates (*P<0.05, **P<0.001). 
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 Increased global histone acetylation in Nkx3.1-deficient prostates 
           Altered expression and enzymatic activity of HDACs in Nkx3.1-mutant mice 
prostates suggest that histone acetylation may be involved in the cell cycle regulation 
by Nkx3.1. To further determine the role of histone acetylation, we performed 
immunohistochemistry assays and examined the global histone acetylation pattern 
(Ac-H3 and Ac-H4) in Nkx3.1-deficient mouse prostate tissues. Our 
immunohistochemical analysis identified global histone hyperacetylation in Nkx3.1-/- 
prostates compared to wild type prostates (Figure 54).    
 
 
 
Figure 54. Increased global histone acetylation in Nkx3.1-deficient prostates: 
Immunohistochemistry analyses indicate significantly increased expression of Ac-H3 and 
Ac-H4 in Nkx3.1-/- prostates (B and D) compared to Nkx3.1+/+ prostates (A and C). 
Quantitation of percentage positive cells (Ac-H3/H4) is shown in panel (E). (*P<0.05)   
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 Up-regulation of cyclins in response to HDAC inhibition  
          Our results so far suggest that high expression of HDACs in Nkx3.1+/+ prostates 
may lead to the lower expression of cyclin D1 and E2. Thus, we hypothesize that 
treatment of wild type prostate tissue with HDAC inhibitor, TSA can induce 
expression of cyclin D1 and cyclin E2. Intriguingly, we observed that both cyclin D1 
and cyclin E2 were significantly up-regulated upon HDAC inhibition in Nkx3.1+/+ 
prostate explants (Figure 55).  
            We next examined the effects of HDAC inhibition on cyclins expression in 
LNCaP cells. Our results showed that cyclin E2 mRNA expression was significantly 
up-regulated in LNCaP cells following TSA treatment. On the other hand, cyclin D1, 
cyclin A2 and cyclin B1 mRNA remained unaffected and showed constant expression 
in vehicle treated or TSA treated samples (Figure 56).     
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Figure 55. Up-regulation of cyclins in response to HDAC inhibition in Nkx3.1 
wild type prostates: Prostate explants were treated with or without HDACi, TSA and 
subsequent QRT-PCR demonstrate that cyclin D1 and E2 were significantly up-
regulated in response to TSA treatment (*P<0.05, **P<0.001). 
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Figure 56. Up-regulation of cyclin E2 in response to HDAC inhibition in 
LNCaP cells: Quantitative RT-PCR analysis in LNCaP cells following TSA 
treatment indicate that cyclin E2 expression was significantly up-regulated 
(**P<0.001) while cyclin D1, cyclin A2 and cyclin B1 expression remained 
unaffected by TSA. 
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Conclusions and Future Directions: 
 
            Based on our preliminary observations, we propose a working model (Figure 
57) in which Nkx3.1 regulates cyclin D1 and cyclin E2 expression and cell cycle exit 
of prostate epithelia, mediated through HDAC1. Our data strongly suggest the 
reduced HDAC1 mRNA expression, protein expression and enzymatic activity in 
Nkx3.1-deficient prostates compared to the wild type prostates. Our study also 
indicates that cyclin D1 and cyclin E2 mRNA levels are up-regulated in Nkx3.1-
deficient mice and NKX3.1 deficient LNCaP cells. As a part of future work, first we 
will confirm our previous findings. Secondly, we will explore the link between 
Nkx3.1 and HDAC1. We will investigate the molecular mechanism of how Nkx3.1 
may be regulating HDAC1 in cell cycle regulation. Recently, Lei and colleagues have 
provided evidence that Nkx3.1 engages in cell cycle and cell death machinery via 
association with HDAC1, leading to increased p53 acetylation and half-life through 
MDM2-dependent mechanisms (Lei et al., 2005). However, neither the precise 
transcriptional regulation nor the exact role of cyclins in cell cycle regulation by 
Nkx3.1 has been explored. It will be interesting to determine if Nkx3.1 directly 
regulates transcriptional activity of cyclin D1 and cyclin E2.  We will perform 
chromatin immunoprecipitation (ChIP) assays to determine the direct in vivo binding 
of Nkx3.1 at the regulatory regions of cyclin D1 and cyclin E2.  
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Figure 57. Model for role of Nkx3.1 in cell cycle regulation: We propose a 
model in which Nkx3.1 regulates cyclin D1 and cyclin E2 expression via 
HDAC1. Nkx3.1 deficiency leads to HDAC1 deficiency, which can alter cyclin 
expression resulting into delayed cell cycle exit. 
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 CHAPTER VII 
 
FUTURE DIRECTIONS AND OVERALL CONCLUSIONS 
 
Future Directions: 
 
           As my dissertation work, we have investigated a molecular mechanism behind 
dosage-sensitive and dosage-insensitive Nkx3.1 target gene regulation. Nevertheless, 
an interesting question still remains unanswered, why is the intelectin gene sensitive 
to the loss of Nkx3.1 dosage while the probasin gene is insensitive? To answer this 
question, we propose two different hypotheses: 1) The number of functional Nkx3.1 
binding sites at these target gene loci is different. I.e. Intelectin gene locus has more 
Nkx3.1 binding sites than the probasin gene locus or vice versa.  2) Nkx3.1 binds at 
these target gene loci with differential binding affinity. I.e. At the probasin gene locus 
Nkx3.1 binds with a stronger affinity than that of the intelectin locus. 
           To investigate these possibilities, we first calculated the binding affinities 
(which are presented as a percentage total input of ChIP) of Nkx3.1 at the intelectin 
(Int5 binding site) and probasin (Pbn1 binding site) promoters. No significant 
difference was observed in the affinities of Nkx3.1 at the intelectin and probasin 
promoter at least at the Int5 site versus Pbn1 site (Figure 58). However, this does not 
rule out binding affinities differences at other Nkx3.1 binding sites at the intelectin 
and probasin gene loci which we have not yet determined.   
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Figure 58. Binding affinities of Nkx3.1 at dosage-sensitive versus 
dosage-insensitive gene loci: Binding affinities were calculated as 
percentages of total input from ChIP assays. No difference was observed in 
the binding affinities of Nkx3.1 at the Int5 site versus Pbn1 site.  
 
 
 
            After this initial assessment regarding binding site affinities, we next searched 
for Nkx3.1 putative binding sequences (TAAGTA/G or C/TACTTA) on the 10 Kb 
upstream and 5 Kb downstream regions of the intelectin and probasin gene loci. We 
found (15+18 =33) putative sites at the intelectin locus and (10+16 =26) putative sites 
at the probasin locus. The schematic of the intelectin and probasin gene loci with 
approximate binding sequence location is shown in (Figure 59).  
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Figure 59. Schematic of the intelectin and probasin gene loci with approximate binding 
sequence location: We examined the sequences of the intelectin and probasin gene loci and 
mapped the putative Nkx3.1 binding sites which are represented as arrows. Green arrow: 
TAAGTG/A; Blue arrow: C/TACTTA; Red arrow: Nkx3.1 bound sites by ChIP analyses (see 
below); Black arrow: Transcription start site (TSS). 
 
 
             
             Next we performed ChIP assays in Nkx3.1 mutant prostates to examine in 
vivo binding of Nkx3.1 at these putative sites. Interestingly, by ChIP analysis, we 
found that 3 out of 33 sites were bound by Nkx3.1 at the intelectin locus. By contrast, 
only 1 out of 26 sites was bound by Nkx3.1 at the probasin locus (Figure 60). These 
preliminary results suggest that difference in number of binding sites may underlie 
the dosage-sensitive or –insensitive nature of Nkx3.1 target genes. However, we need 
to confirm these binding sites with more number of mice and ChIP assays.   
 
 139
 Input IgG IgNkx
 
 
Figure 60. ChIP assays to demonstrate direct in vivo binding of Nkx3.1: ChIP 
assays identify 3 binding sites at the intelectin gene locus and 1 binding site at the 
probasin gene locus. Note the Nkx3.1 binding at the Int5 and Pbn1 sites which we 
have demonstrated earlier. 
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 Overall Conclusions: 
 
            Magee and colleagues originally proposed a concept of dosage-sensitive, 
stochastic Nkx3.1 target gene regulation in prostate cancer haploinsufficiency (Magee 
et al., 2003) however; neither the underlying molecular mechanism nor the functional 
relevance of Nkx3.1 target genes in prostate cancer has been investigated. Here, we 
have explored the molecular basis of the dosage-sensitive and stochastic Nkx3.1 
target genes and demonstrated the functional significance of one of the Nkx3.1 
dosage-sensitive target, intelectin / omentin in prostate tumorigenesis.  
            We examined the dosage-sensitive and dosage-insensitive Nkx3.1 target gene 
regulation in Nkx3.1-mutant mice which is a model for prostate tumor initiation 
(Abdulkadir et al., 2002). Based on our results we propose a model in which dosage-
sensitive (intelectin) and dosage-insensitive (probasin) target gene loci show 
differential histone acetylation pattern and differential Nkx3.1/PCAF binding in vivo 
which correlates with their expression. Our results strongly suggest the role for 
chromatin accessibility in the dosage-sensitive and -insensitive Nkx3.1 target gene 
regulation. Although our data strongly support a chromatin accessibility model, other 
possibilities could account for the differential dosage-sensitivity of Nkx3.1 target 
genes. Formation of differential protein complexes with different interactions at the 
dosage-sensitive (intelectin) versus dosage-insensitive (probasin) target genes 
promoters or acetylation of Nkx3.1 itself as a key concentration dependent event can 
not be ruled out at this point. Nevertheless, our results emphasize the role for 
epigenetic modifications (histone acetylation) in selective inactivation of dosage-
sensitive target genes important for tumorigenesis and other developmental disorders 
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 caused by transcription factor haploinsufficiency. Moreover, we demonstrate direct in 
vivo binding of Nkx3.1 at the target gene promoters by ChIP assays suggesting direct 
regulation of these genes by Nkx3.1. Lastly, we report a very novel finding that 
Nkx3.1 can associate with histone acetyl transferase (HAT), PCAF and to our 
knowledge neither PCAF nor any other HAT has been shown to be associated with 
Nkx3.1. The finding supports the notion that Nkx3.1 can act as a transcriptional 
activator in vivo.  
             In addition to the mechanism of dosage-sensitive Nkx3.1 target gene 
regulation, we explore the functional significance of one of the dosage-sensitive 
target intelectin / omentin in prostate cancer. Here, we provide evidence that 
intelectin / omentin can suppress prostate tumorigenicity in vivo in prostate cancer. 
Our series of in vitro studies including cell growth analyses, MTT assays and soft 
agar colony formation assays suggest that intelectin /omentin may have a tumor 
suppressor-like activity in prostate cells. Consistent with in vitro studies, our nude 
mice xenograft studies indicate that intelectin / omentin is a bona-fide tumor 
suppressor in prostate cancer in vivo. These findings provide the first piece of 
functional evidence for Nkx3.1 target genes in prostate tumorigenesis. Furthermore, 
our study underscores the importance of functional characterization of dosage-
sensitive and -insensitive Nkx3.1 target genes that could illuminate the molecular 
pathways involved in prostate tumorigenesis. 
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